


























































autoimmune	 disorder	with	 evidence	 of	 circulating	 pathogenic	 ANCA.	 There	 are	 two	main	
antigenic	 targets:	 proteinase	 3	 (PR3)	 and	myeloperoxidase	 (MPO).	 Previous	 genome-wide	














were	 identified:	 three	 associated	 with	 PR3-AAV	 (BCL2L11-MIR4435-2HG,	 EBF3-MGMT,	
IGHV1-69),	two	with	MPO-AAV	(BACH2,	ANKRD11-SPG7)	and	two	shared	by	both	(CTLA-4	and	























































































































































































































































































































































































































































































Although	 polyarteritis	 nodosa	 (PAN)	 was	 first	 described	 as	 a	 disease	 entity	 by	 Carl	 von	
Rokitansky	in	1852	(1),	the	first	description	of	necrotising	vasculitis	was	attributed	to	Adolf	
Kussmaul	and	Rudolf	Maier	in	1866,	who	reported	a	case	of	systemic	syndrome	affecting	the	
nervous	 system	 and	 kidneys	 of	 a	 young	man.	 They	 described	 the	 gross	 and	microscopic	
pathology	 of	 the	 disease	 which	 consisted	 of	 focal,	 inflammatory	 arterial	 nodules	 in	 the	
medium	and	small-sized	arteries	and	named	it	“periarteritis	nodosa”	(2).	It	was	not	until	1903	
that	 Ferrari	 in	 Trieste,	 Italy	 suggested	 the	 name	 “polyarteritis	 nodosa”	 to	 emphasise	 the	
transmural	inflammation	of	the	vessel	wall	that	characterises	this	vasculitis	(3),	which	remains	








Wegener’s	 in	 1954	 (7),	 though	 the	 eponym	 has	 recently	 been	 dropped	 in	 the	 wake	 of	
emergence	of	evidence	linking	Wegener	to	the	Nazi	regime	during	World	War	II	(8).	Churg	
and	Godman	were	also	the	first	to	describe	that	microscopic	polyarteritis,	WG	and	allergic	
angiitis	 and	 granulomatosis	 (Churg-Strauss	 syndrome)	 were	 different	 from	 PAN	 based	
primarily	on	the	pathological	features	(7),	which	was	later	supported	by	the	findings	of	many	





Around	 the	 same	 time	 of	 the	 discovery	 of	 vasculitis	 affecting	 the	medium-sized	 arteries,	
Schönlein	 (16),	 Henoch	 (17,	 18)	 and	Osler	 (19,	 20)	 identified	 a	 form	 of	 purpura	 that	was	
accompanied	by	arthralgias,	abdominal	pain	and	nephritis.	The	histological	examination	of	
these	purpuric	 lesions	demonstrated	 inflammation	of	 small	 dermal	 vessels	with	extensive	
leukocytoclasia	 and	 IgA-dominant	 immune	 deposits	 in	 the	 vessel	 wall	 (21),	 which	 is	 now	
termed	 IgA	 vasculitis.	 As	most	 of	 the	 clinical	 and	 pathological	manifestations	 of	 systemic	
vasculitides	were	identified	before	the	end	of	twentieth	century,	our	understanding	of	the	















Classification	 of	 disease	 is	 the	 process	 of	 categorising	 illnesses	 in	 a	 larger	 framework	 of	











which	 include	giant	cell	arteritis	 (GCA),	Takayasu	arteritis	 (TAK),	eosinophil	granulomatosis	






classification	 of	 ANCA-associated	 vasculitis	 (AAV).	 Furthermore,	 the	 introduction	 of	 new	
radiological	 diagnostic	 techniques	 (e.g.	 computed	 tomography	 and	 magnetic	 resonance	










involved,	 but	 added	 several	 important	 categories	 comprising	 of	 variable	 vessel	 vasculitis.	
These	 include	 Behcet’s	 disease	 and	 Cogan’s	 syndrome,	 single	 organ	 vasculitis,	 vasculitis	
associated	with	systemic	disease	and	vasculitis	associated	with	a	probable	aetiology	as	well	
as	subcategories	which	include	division	of	SVV	into	immune	complex,	ANCA-associated,	anti-
glomerular	 basement	 membrane	 and	 hypocomplementemic	 urticarial	 vasculitis.	 It	 also	










of	GPA	consisting	of	 laboratory,	 radiological,	histological	and	clinical	manifestations	of	 the	




The	 existing	 classification	 criteria	 are	 useful	 but	 there	 is	 no	 doubt	 that	 there	 are	 some	
shortcomings	 given	 the	 evolving	 diagnostic	 tools,	 discovery	 of	 novel	 biomarkers,	 better	
understanding	of	the	disease	pathogenesis	and	recent	genetic	studies	which	have	highlighted	
the	 difference	 between	 GPA	 and	 MPA.	 Interestingly,	 Mahr	 and	 colleagues	 employed	 an	
unsupervised	 machine	 learning	 algorithm	 -	 cluster	 analysis	 to	 identify	 subgroups	 of	 AAV	
patients.	They	have	successfully	defined	five	clusters	with	distinct	mortality	and	relapse	rates	
using	 four	 variables	 consisting	 of	 ANCA	 specificity,	 renal,	 cardiac	 and	 gastrointestinal	
involvement	 (28),	 suggesting	 this	 subgrouping	might	 be	 aetiologically	 and	 therapeutically	
relevant	and	 requires	 further	validation.	A	global	 study	 -	The	Diagnostic	and	Classification	
Criteria	for	Vasculitis	Study	(DCVAS)	which	began	in	2010,	is	currently	underway	to	develop	
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AAV	 in	 various	 ethnic	 groups.	 A	 number	 of	 candidate	 gene	 approach	 studies	 have	 been	
performed	over	the	years	but	the	success	of	this	approach	depends	 largely	on	the	chosen	
genes	 or	 pathways	 studied.	 The	 understanding	 of	 genetics	 in	 AAV	 has	 only	 substantially	
improved	following	the	genome-wide	association	studies	(GWAS)	conducted	by	the	European	








of	 transplantation,	 strong	 association	 to	 various	 autoimmune	 disorders	 (56)	 as	 well	 as	
susceptibility	and	resistance	to	a	range	of	bacterial	and	viral	infections	(57).	One	of	the	most	
striking	 features	 observed	 is	 that	 autoimmune	 diseases	with	 characteristic	 antibodies	 are	
generally	 associated	 with	 HLA	 class	 II	 alleles,	 whereas	 seronegative	 diseases	 most	 often	








is	 the	 discovery	 of	 epistatic	 interaction	 between	HLA-B27	 and	HLA-B40	with	 endoplasmic	
reticulum	 aminopeptidase	 1	 (ERAP1)	 in	 AS	 (58,	 60).	 ERAP1	 has	 dual	 functions:	 it	 works	
together	with	endoplasmic	reticulum	aminopeptidase	2	(ERAP2)	in	endoplasmic	reticulum	to	
trim	and	present	peptides	on	HLA	class	 I	molecules	and	 it	 is	 involved	 in	cytokine	receptor	
shedding	 such	 as	 tumour	 necrosis	 factor	 receptor	 I,	 IL-1	 receptor	 2	 and	 IL-6Ra.	 This	
interaction	 supports	 the	 disease	 model	 where	 aberrant	 trimming	 of	 peptides	 or	 antigen	
presentation	by	ERAP1	are	 involved	in	the	pathogenesis	AS	together	with	abnormalities	 in	





region	 contains	 genes	 that	 have	 functions	 related	 to	 antigen	 processing	 (TAP,	 LMP)	 or	
presentation	(HLA-DR,	HLA-DQ	and	HLD-DP)	and	the	class	III	region	is	the	most	gene-dense	
region	in	the	human	genome	comprising	of	many	innate	immunity	related	genes	including	
cytokines	 tumour	 necrosis	 factor	 (TNF)	 and	 complement	 as	 well	 as	 non-immune	 related	
genes.	 The	 major	 differences	 between	 MHC	 class	 I	 and	 class	 II	 genes	 and	 functions	 are	
summarised	 in	 Table	 1.1	 (62,	 63).	 The	 International	 Immunogenetic	 Information	 system®	
(IMGT)	HLA	database	is	a	very	useful	resource	that	contains	a	compilation	of	sequences	of	
































































Study,	Year	 Population	 HLA	 Cases/Controls	 OR	 P-value	
Spencer,	1992	 British	 HLA-DQw7	 34	GPA	&	25	MPA/1,103	 2.90	 <2.50	x	10-3	
HLA-DR3	 0.31	 <1.00	x	10-2	
Papiha,	1992	 British	 HLA-DR1	 27	GPA/105	 2.30	 4.00	x	10-2	
Hagen,	1995	 Dutch	 HLA-DR6	 224	AAV/2,443	 0.43	 <4.00	x	10-3	
HLA-DR13	 0.32	 <2.00	x	10-3	
Gencik,	1999	 German	 HLA-DRB1*13	 76	PR3/na	 0.40	 <5.00	x	10-2	
HLA-DQB1*06:03	 0.20	 <5.00	x	10-3	
Tsuchiya,	2003	 Japanese	 HLA-DRB1*09:01	 64	MPO/na	 2.44	 1.40	x	10-3	








Heckmann,	2007	 German	 HLA-DPB1*04:01	 282	GPA/380	 3.01	 2.31	x	10-21	
Stassen,	2009	 Dutch	 HLA-DR6	 304	AAV/9,872	 0.30	 <1.00	x	10-4	
HLA-DR4	 1.70	 <1.00	x	10-4	
Luo,	2011	 Chinese	 HLA-DRB1*14:54	 152	AAV/200	 0.02	 1.70	x	10-2	
HLA-DRB1*11:01	 107	MPA/200	 2.53	 2.30	x	10-2	
†Lyons,	2012	 European	 HLA-DP	(rs3117242)	 1,521	PR3/6,858	 7.03	 6.20	x	10-89	
HLA-DQ	(rs5000634)	 556	MPO/6,858	 0.65	 2.10	x	10-8	
†Xie,	2013	 North	
American	
HLA-DPB1	(rs9277554)	 750	GPA/1,820	 0.24	 1.92	x	10-50	
Wu,	2015	 Chinese	 HLA-DPB1	(rs3117242)	 100	GPA/485	 2.09	 6.24	x	10-5	




HLA-DPB1	(rs141530233)	 1,361	PR3/4,723	 6.19	 1.33	x	10-106	
























diseases,	 including	 type	 1	 diabetes	 (T1D),	 rheumatoid	 arthritis	 (RA)	 and	 systemic	 lupus	












which	 PiZ	 and	 PiS	 are	 the	most	 common	 and	 clinically	 significant	 alleles.	 A1AT	 deficiency	
clinically	manifests	in	individuals	carrying	mutations	of	both	gene	Pi	alleles,	especially	in	the	
















Study,	Year	 Population	 SERPINA1	 No.	of	Cases	 OR	 P-value	
Elzouki,	1994	 Swedish	 PiZ	allele	 88	AAV	(66	GPA)	 6.00	 1.00	x	10-4	
Borgmann,	2001	 German	 PiZ	allele	 79	GPA	 3.50	 <1.00	x	10-4	
Mahr,	2010	 German	 PiZ	and	PiS	alleles	 433	GPA	 14.58	 2.00	x	10-3	
†Lyons,	2012	 European	 §rs7151526	 1,521	PR3	 0.53	 5.60	x	10
-12	
†Xie,	2013	 North	American	 rs1956707	 987	GPA	 na	 9.00	x	10-3	
Pervakova,	2016	 Russian	 PiZ	and	PiF	alleles	 38	GPA	 9.68	 3.42	x	10-2	
†Merkel,	2016	 North	American	 §rs28929474	 1,361	PR3	 2.43	 1.29	x	10
-13	
	

















is	known	to	bind	 to	CD80	and	CD86	with	markedly	higher	affinity	 than	CD28.	However,	 it	
functions	 as	 a	 CD28	 antagonist	 and	 has	 an	 essential	 inhibitory	 role	 in	 the	 regulation	 of	
immune	 responses.	 Hence,	 the	 B7-CD28/CTLA-4	 pathway	 is	 crucial	 in	 regulating	 T-cell	




has	 demonstrated	 promising	 results	 in	 improving	 survival	 of	melanoma	 through	 tumour-






and	 Hashimoto’s	 thyroiditis	 (93-96),	 coeliac	 disease	 (97),	 alopecia	 (98),	 Crohn’s	 disease,	
ulcerative	colitis	(UC),	primary	sclerosing	cholangitis	(PSC),	psoriasis	and	AS	(99).	A	list	of	the	












Study,	Year	 Population	 CTLA4	 Cases/Controls	 OR	 P-value	
Huang,	2000	 Swedish	 CTLA4	(AT)	86	repeat	 32	GPA/109	 na	 <1.60	x	10-3	
Giscombe,	2002	 Swedish	 rs5742909	 32	GPA/122	 2.04	 2.59	x	10-2	
Tsuchiya,	2003	 Japanese	 na	 69	AAV/na	 na	 ns	
Zhou,	2004	 North	
American	
CTLA4	(AT)	86	repeat	 117	GPA/123	 0.38	 1.00	x	10-3	
Spriewald,	2005	 German	 rs231775	 32	GPA/91	 na	 ns	
rs5742909	




Kamesh,	2009	 British	 rs231775	 222	AAV/629	 1.32	 1.00	x	10-2	
rs3087243	 0.67	 1.00	x	10-4	
Carr,	2009	 British	 rs3087243	 575	AAV/9,040	 0.84	 6.40	x	10-3	
†Lyons,	2012	 European	 rs16840252	 2,267	AAV/6,858	 0.87	 1.28	x	10-5	
Chung,	2012	 North	
American	




rs231726	 987	GPA/2,731	 na	 3.00	x	10-3	
rs3096851	 na	 3.00	x	10-3	
Wu,	2017	 Chinese	 rs231775	 176	AAV/485	 1.04	 ns	
rs5742909	 1.02	 ns	
	









which	 initiates	transcription	at	the	 intron	1	promoter.	The	canonical	 isoform	is	 involved	in	





(113,	114)	or	by	 isolation	procedure	 (115).	This	key	process	 is	 called	priming	and	 it	 is	 the	
membrane-bound	 form	 of	 the	 PR3	 that	 is	 able	 to	 interact	 with	 the	 ANCA,	 precipitating	
neutrophil	 activation	 and	 endothelial	 adhesion.	 Halbwachs-Mecarelli	 and	 colleagues	
previously	demonstrated	that	there	is	a	bimodal	distribution	of	membrane	PR3	expression	
(mPR3+/-)	 and	 the	 proportion	 of	 mPR3+	 and	 mPR3-	 cells	 remains	 highly	 stable	 despite	
priming	 and	 over	 prolonged	 periods	 of	 time	 in	 a	 given	 individual	 (116).	 This	 finding	 was	
subsequently	replicated	(117)	and	more	importantly,	the	authors	also	reported	that	a	high	

























Abdgawad	M	 and	 colleagues	 also	 reported	 similar	 findings	 involving	 a	 cohort	 of	 63	 AAV	
patients	 and	 107	 healthy	 controls.	 They	 found	 that	 AAV	 patients	 had	 increased	 plasma	
concentrations	of	PR3	as	well	as	mPR3-positive	neutrophils	compared	to	healthy	controls,	but	





Protein	 tyrosine	 phosphatase,	 non-receptor	 type	 22,	 also	 known	 as	 lymphocyte	 tyrosine	
phosphatase,	is	a	protein	that	is	encoded	by	the	PTPN22	gene	and	is	primarily	expressed	in	
lymphoid	tissues.	The	important	role	of	PTPN22	as	a	risk	factor	for	autoimmunity	was	first	
recognized	with	 the	association	of	a	missense	SNP	 (1858C>T;	 rs2476601;	R620W)	with	an	
increased	risk	of	T1D	(91-93,	124,	125)	and	it	encodes	an	arginine	to	tryptophan	substitution	
at	 amino	 acid	 620	 (Arg620Trp)	 in	 the	 first	 proline-rich	motif	 of	 the	 PTPN22	 protein.	 This	












with	 four	 proline-rich	 regions	 facilitating	 interaction	 with	 other	 proteins.	 In	 the	 adaptive	


















A	 series	 of	 approaches	 including	 transfected	 cell	 lines,	 primary	 human	 lymphocytes	 and	
animal	models	 have	 been	 employed	 to	 understand	 how	 the	 genetic	 risk	 variant	 (PTPN22	
Arg620Trp)	 contributes	 to	 development	 of	 autoimmunity.	 In	 Jurkat	 T	 cells	 lines,	 co-






could	be	due	 to	 the	 relative	expression	 levels	of	PTPN22	and	Csk,	where	 in	 the	setting	of	
limiting	Csk,	the	localisation	of	PTPN22	to	the	cell	membrane	may	be	enhanced	and	therefore	







Study,	Year	 Population	 PTPN22	 Cases/Controls	 OR	 P-value	
Jagiello,	2005	 German	 rs2476601	[A]	 199	GPA/399	 1.75	 2.00	x	10-3	
Carr,	2009	 British	 rs2476601	[A]	 641	AAV/9,115	 1.40	 1.40	x	10-4	





rs2476601	[A]	 230	AAV/1,178	 1.45	 3.68	x	10-2	
Chung,	2012	 North	
American	
rs2476601	[A]	 895	GPA/1,976	 1.35	 2.00	x	10-3	
†Lyons,	2012	 European	 rs6679677	[A]	 1,353	AAV/1,599	 0.80	 2.60	x	10-1	
†Xie,	2013	 North	
American	
rs2476601	[T]	 750	GPA/1,820	 na	 6.00	x	10-3	
†Merkel,	2016	 North	
American	
rs2476601	[A]	 1,986	AAV/4,723	 1.36	 1.86	x	10-7	
1,361	PR3/4,723	 1.33	 3.19	x	10-5	
378	MPO/4,723	 1.64	 5.85	x	10-6	










of	 PTPN22	 Trp620	 in	 immune	 responses.	 Vang	 et	 al	 demonstrated	 that	 T	 cells	 from	 T1D	
patients	carrying	PTPN22	Trp620	produce	less	interleukin-2	(IL-2)	upon	TCR	stimulation	(143)	
and	 this	 was	 subsequently	 confirmed	 in	 a	 larger	 cohort	 (145).	 A	 consistent	 finding	 was	
demonstrated	 in	 healthy	 controls	 where	 T	 cells	 from	 individuals	 carrying	 the	 risk	 allele	
(PTPN22	Trp620)	were	found	to	have	blunted	Ca2+	flux,	IL-2	and	IL-10	production	following	
anti-CD3	 stimulation	 and	 the	 effects	 were	 most	 pronounced	 in	 the	 memory	 T	 cell	




frequencies	of	 thymically-derived	Tregs	 in	 the	peripheral	blood	of	SLE	patients,	 as	well	 as	
increased	PD-1	expression	on	both	Tregs	and	effector	T	cells	 (148).	 In	addition,	 studies	of	











thymus	 and	 spleen,	 accompanied	 by	 expanded	 memory/effector	 T	 cell	 populations	 and	
hyperresponsiveness	 in	 both	 lymphocyte	 and	 dendritic	 cells,	 consistent	 with	 a	 loss-of-
function	effect	(151).	Similarly,	Dai	and	colleagues	also	generated	knock-in	mice	expressing	
PEP	R619W	which	displayed	T-cell	expansion,	transitional,	germinal	center	and	age-related	B-




effector	memory	 T	 cells.	 However,	 the	 discordant	 response	 to	 antigen-receptor	 triggered	
signalling	 between	 human	 and	murine	 studies	where	 human	memory	 T	 and	 B	 cells	 from	
individuals	 carrying	 the	 risk	 variant	 exhibit	 significantly	 blunted	 signals	 upon	 intracellular	




















Graham	 et	 al	 reported	 a	 haplotype	 of	 the	 IRF5	 gene	 to	 be	 a	 risk	 factor	 for	 SLE.	 More	
interestingly,	this	haplotype	was	shown	to	be	functionally	relevant.	Firstly,	rs2004640	T	allele	
alters	 a	 consensus	 splice	 donor	 site	 leading	 to	 expression	 of	 IRF5	 isoforms	 bearing	 an	











Two	 previous	 studies	 investigated	 polymorphisms	 within	 IRF5	 in	 AVV	 patients	 with	
contradictory	 results.	 In	 a	 German	 cohort	 consisting	 of	 601	 GPA	 cases	 and	 827	 controls,	
Wieczorek	et	al	identified	a	four	SNP	haplotype	of	IRF5	as	described	earlier,	which	conferred	
a	 protective	 effect	 in	 GPA	 patients	 (rs2004640/rs60344245/rs2070197/rs10954213;	
G/ins/T/G;	OR	=	0.73,	pc	=	0.0012,	CI	0.62-0.85)	a	similar	trend	to	that	observed	in	SLE	(170).	


















surface	 upon	 activation.	 FcgR	 plays	 crucial	 role	 in	 initiation	 and	 regulation	 of	 antibody-












pathogens,	 known	 as	 pathogen	 associated	 molecular	 patterns	 (PAMPs).	 The	 interaction	
between	TLRs	and	PAMPs	triggers	intracellular	signals	and	promotes	inflammatory	response	
		 21	
such	 as	 via	 type	 1	 IFN	 and	 pro-inflammatory	 cytokine	 production	 (179).	 Husmann	 et	 al	
previously	 investigated	 the	 associations	 of	 four	 SNPs	 (rs352162,	 rs352140,	 rs352139	 and	
rs5743836)	within	TLR9	in	AAV	patients	comprising	of	646	GPA,	164	EGPA	and	53	MPA.	They	
found	 that	 all	 four	 SNPs	 were	 strongly	 associated	 with	 GPA	 and	 interestingly,	 significant	
associations	were	also	identified	in	MPA	but	each	with	the	contrary	allele.	A	much	stronger	
association	 was	 observed	when	 they	 compared	 cases	 to	 controls	 according	 to	 the	 ANCA	
















Reynolds	 and	his	 colleagues	previously	 looked	at	 patients	with	different	 types	of	AAV	 for	
clinical	associations	with	-463G/A	SNP.	They	demonstrated	that	GG	genotype	was	associated	
with	 an	 increased	 incidence	 of	 vasculitis	 in	 female	 MPO-AAV	 only	 while	 there	 was	 an	
association	of	the	GA/AA	genotypes	with	an	increased	relapse	rate	in	patients	with	MPO-AAV	
(187).	 The	authors	 suggested	 that	 the	G	and	A	alleles	might	be	differentially	 regulated	 in	







The	b2	 integrin	 (CD18)	 is	a	protein	 that	 is	encoded	by	 the	 ITGB2	gene	which	 is	 located	at	
chromosome	 21q22.3.	 It	 is	 the	 common	 b-subunit	 of	 several	 different	 heterodimers:	
lymphocyte	 function-associated	antigen	1	 (LFA-1),	macrophage-1	antigen	 (Mac-1),	 integrin	
alphaXbeta2	and	integrin	alphaDbeta2.	Integrins	are	known	to	participate	in	cell	adhesion	as	
well	 as	 cell-surface	mediated	 signalling.	Mutations	 in	 ITGB2	 results	 in	 leukocyte	 adhesion	
deficiency	type	1	(LAD-1)	where	individuals	present	in	early	infancy	with	failure	of	umbilical	













summarised	 in	Table	1.6	 (72,	100,	106,	192-202).	Most	of	 the	variants	are	 involved	 in	 the	













Study,	Year	 Population	 Gene	(variant)	 Cases	/	Controls	 OR	 P-value	
Papiha,	1992	 British	 Complement	C4B	 27	GPA/163	 2.56	 4.00	x	10-2	
Finn,	1994	 British	 Complement	C3F	 63	AAV/na	 2.60	 <2.5	x	10-2	
Persson	U,	1999	 Swedish	 Complement	C3F	 37	PR3/101	 1.88	 <5.00	x	10-2	
Murakozy,	2001	 German	 IL-10-1082	 39	GPA/72	 0.72	 <5.00	x	10-2	
Zhou,	2002	 Swedish	 IL-10	promoter	microsatellite	 32	GPA/109	 na	 <5.00	x	10-2	
Spriewald,	2005	 German	 IL-10-1082,	-819,	-592	haplotype	 32	GPA/91	 na	 ns	
IFNG	+874	(A/T)	 3.14	 §2.7	x	10-2	
TNF	promoter	-238	(G/A)	 5.01	 §2.9	x	10-2	
Miyashita,	2006	 Japanese	 KIR2DS3	 43	MPA/239	 0.24	 3.8	x	10-2	
Mamegano,	
2008	
Japanese	 LILRA2	(rs2241524)	 50	MPA/284	 2.52	 4.9	x	10-2	
Wieczorek,	
2009	
German	 CD226	 642	GPA/1,226	 1.23	 3.1	x	10-3	
Carr,	2009	 British	 CD226	(rs763361)	 641	AAV/9,115	 0.90	 2.1	x	10-1	
IL-2RA	(rs41295061)	 675	AAV/8,936	 0.77	 1.22	x	10-2	
Wieczorek,	
2010	




Zhou,	2012	 Chinese	 DEFB4	CNV	 112	AAV/523	 na	 9.00	x	10-3	
Wu,	2014	 Chinese	 TLR2	(rs3804100)	 76	MPA/501	 na	 1.80	x	10-2	
	
AAV,	ANCA-associated	 vasculitis;	CD226,	 cluster	 of	 differentiation	 226;	 CNV,	 copy	number	 variation;	DEFB4,	
defensin	beta	4A;	GHSR,	growth	hormone	secretagogue	receptor;	GPA,	granulomatosis	with	polyangiitis;	IFNG,	
interferon	 gamma;	 IL2RA,	 interleukin-2	 receptor	 alpha	 chain;	 IL-10,	 interleukin-10;	 KIR2DS3,	 killer	 cell	
immunoglobulin-like	 receptor,	 two	 Ig	 domains	 and	 short	 cytoplasmic	 tail	 3;	 LEPR,	 leptin	 receptor;	 LILRA2,	







of	 MPO	 and	 PR3	 as	 the	 antigenic	 targets	 which	 paved	 the	 foundation	 of	 our	 current	
understanding	 of	 AAV,	 ANCA	 has	 become	 an	 important	 diagnostic	 marker	 and	 in	 most	
laboratories,	screening	for	ANCA	is	done	by	an	indirect	immunofluorescence	technique	using	
human	 buffy	 coat	 cells	 as	 substrate.	 Sera	 positive	 for	 ANCA	 are	 further	 tested	 by	 direct	
enzyme	 immunoassay	 (EIA)	 to	 reveal	 their	 specificity	 for	 either	purified	PR3	or	MPO	as	 a	




have	 no	 detectable	 ANCA	 (204).	 The	 cause	 of	 injury	 in	 ANCA-negative	 patients	 remains	
uncertain	 and	 whether	 this	 could	 be	 due	 to	 antibodies	 which	 cannot	 be	 detected	 using	
currently	available	immunoassays	or	epitope	specificity	remains	unknown	(205,	206).	Several	
other	possibilities	have	been	raised	including	inhibition	of	assays	for	anti-MPO	antibodies	by	




the	 late	 90s.	 The	 autoantibodies	 against	 hLAMP-2	were	 found	 in	 untreated	 AAV	 patients	




AAV	predominantly	 affects	 the	 small	 vessels	 in	 the	body	 (arteries,	 arterioles,	 venules	 and	
veins).	 In	 the	 acute	 phase,	 AAV	 is	 characterised	 a	 necrotizing	 vasculitis	 with	 infiltrating	
neutrophils	 and	 monocytes.	 Within	 days,	 the	 neutrophils	 undergo	 leukocytoclasis	 and	
disappear,	to	be	replaced	by	mononuclear	leukocytes	including	macrophages,	monocytes	and	
















(211).	 Bansal	 and	 Tobin	 reported	 a	 case	 of	 transplacental	 transfer	 of	MPO-ANCA	 from	 a	
mother	to	a	33-week	gestational	age	neonate	resulting	in	neonatal	pulmonary	haemorrhage	









AAV	 development	 with	 specific	 drugs,	 such	 as	 propylthiouracil,	 minocycline,	 pimagedine,	
hydralazine,	allopurinol,	D-penicillamine,	phenytoin,	isotretinoin	and	lemivasole-adulterated	
























in	 the	 absence	 of	 contribution	 from	 the	 cellular	 immune	 response,	 supporting	 the	
pathogenicity	of	MPO-ANCA.	Although	the	degree	of	disease	observed	was	mild,	this	model	








PR3	 antibodies	 have	 been	 reported.	 Furthermore,	 similar	 approaches	 as	 described	 were	
employed	 to	 generate	 an	 animal	 model	 for	 PR3-AAV	 but	 proved	 unsuccessful	 in	 initial	










derived	 from	 patients	 with	 severe	 systemic	 vasculitis,	 these	 mice	 developed	 mild	





PR3	 (rmPR3)	 led	 to	 NCGN	 in	 immunodeficient	 NOD-SCID	 recipients,	 but	 no	 disease	 was	





tool	 for	 investigating	 the	molecular	mechanisms	of	downstream	events	once	 the	 immune	
tolerance	is	broken.	
	
Both	MPO	and	PR3	are	 typically	 found	 in	 the	cytoplasmic	azurophilic	neutrophil	 granules.	
Several	 in	 vitro	 studies	 showed	 that	 ANCA	 can	 activate	 neutrophils	 and	 mononuclear	
phagocytes	by	binding	to	 their	cognate	antigen	on	the	cell	 surface	after	priming	with	TNF	
(113,	 225),	 causing	 an	 oxidative	 burst	 with	 release	 of	 reactive	 oxygen	 species	 (ROS),	
degranulation	 with	 release	 of	 MPO,	 elastase	 and	 PR3	 (113,	 223,	 225),	 secretion	 of	 pro-
inflammatory	cytokines	(226)	and	upregulation	of	cell	adhesion	molecules,	which	promotes	












with	 HLA-DP	 while	 MPO-AAV	 was	 associated	 with	 HLA-DQ	 (70).	 These	 findings	 strongly	
support	a	pathogenic	model	for	PR3-AAV	in	which	an	altered	availability	of	PR3	autoantigen	
(as	recently	demonstrated	by	Merkel	et	al	where	the	PR3-AAV	risk	allele	(rs62132293:G)	is	
associated	with	a	higher	expression	of	PRTN3	 in	neutrophils)	 (71),	 together	with	 impaired	
functional	suppression	by	A1AT	which	is	a	natural	physiological	inhibitor	of	PR3,	prompt	the	




As	with	most	 autoimmune	diseases,	 the	 exact	 aetiologies	 of	AAV	are	not	 known,	 but	 are	
undoubtedly	 multifactorial	 with	 a	 combination	 of	 genetic	 predisposition,	 environmental	
exposure	 and	 characteristics	 of	 the	 immune	 system	 likely	 responsible.	 There	 is	 increasing	



















AAV	 (42)	 and	 the	 reduction	 in	 relapse	 following	 treatment	 with	 co-trimoxazole	 (231).	
However,	these	findings	have	not	been	confirmed	by	another	group	(232)	and	immunisation	
of	Wistar	rats	with	S.	aureus	did	not	induce	vasculitis	or	NCGN	(233).	Though	intriguingly,	the	














induce	 apoptosis	 in	 endothelial	 cells	 in	 a	 similar	 fashion	 to	 ANCA	 MPO	 and	 PR3	 IgG.	
Furthermore,	they	characterised	two	epitopes	that	were	recognised	by	the	autoantibodies	to	
hLAMP-2	 and	one	of	which	 (LAMP-2	 epitope	P41-49)	 has	 complete	homology	with	 FimH,	 a	
bacterial	 adhesion	 molecule.	 Rats	 immunized	 with	 FimH	 produced	 antibodies	 to	 rat	 and	


















components	 of	 NETs	 were	 found	 in	 the	 vicinity	 of	 neutrophil	 infiltrates	 in	 the	 affected	
glomeruli	and	interstitium	of	AAV	patients.	Therefore,	it	has	been	suggested	that	NETs	might	
play	a	role	 in	the	development	of	autoimmune	diseases	due	to	the	persistent	exposure	of	






AAV.	 As	 discussed	 in	 section	 1.5.2,	 neutrophils	 represent	 both	 the	 target	 cells	 of	 the	
autoimmune	response	and	key	effector	cells	triggering	endothelial	cell	damage.	Mice	lacking	
circulating	neutrophils	have	been	shown	to	be	protected	from	anti-MPO	IgG-induced	NCGN	





elevation,	 it	 has	 been	 speculated	 that	 ANCA-activated	 neutrophils	 could	 be	 an	 important	
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source	of	BLyS	 (243).	This	 is	 further	 supported	by	an	 in	vitro	 study	by	Holden	et	al	which	
demonstrated	 ANCA	 induced	 production	 and	 release	 of	 BLyS	 from	 activated	 neutrophils,	
promoting	B-cell	survival	(244).	
	
There	has	 also	been	growing	 interest	 in	 recent	 years	of	 the	 role	of	 T	 cells	 in	AAV,	where	
evidence	 has	 emerged	 supporting	 its	 role	 in	 the	 pathogenesis	 of	 AAV.	 Firstly,	 ANCA	
production	is	T-cell	dependent	where	B	cells	require	stimulation	from	antigen-specific	CD4+	
T	 cells	 to	 generate	 high	 affinity	 class-switched	 antibodies	 (245).	 Secondly,	 in	 addition	 to	
granulomas,	extensive	T-cell	infiltration	in	different	renal	compartments	are	commonly	found	




with	 disease	 activity	 (249).	 McKinney	 et	 al	 recently	 identified	 and	 validated	 a	 novel	
transcriptional	signature	in	CD8+	T	cells	with	prognostic	and	clinical	relevance	in	AAV	patients	
and	 that	 was	 enriched	 for	 genes	within	 the	 IL-7	 and	 TCR	 signalling	 pathways	 (250,	 251).	
Furthermore,	several	studies	have	consistently	demonstrated	defective	regulatory	T	cell	(Treg)	
suppressive	function	in	AAV	patients	despite	conflicting	results	regarding	the	number	of	Treg	









contrast,	 a	 distinct	 B	 cell	 subset	 with	 immunoregulatory	 properties	 has	 been	 termed	
regulatory	 B	 cells	 (Breg).	 They	 are	 characterised	 by	 high	 CD5	 surface	 expression	 and	 IL-10	
production	(258),	which	promote	the	development	of	Treg	and	inhibit	the	differentiation	of	
naïve	 T	 cells	 into	 Th1	 or	 Th17	 cells	 (259).	 Several	 studies	 have	 demonstrated	 a	 lower	
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is	 a	potent	neutrophil	 chemoattractant,	 has	been	demonstrated	by	 Schreiber	 et	 al	where	
ANCA-stimulated	 neutrophils	 released	 C5a,	 acting	 on	 C5a	 receptor	 (C5aR),	 which	 in	 turn	
recruited	and	primed	more	neutrophils,	resulting	in	an	amplification	loop	(265).	Importantly,	











reactive	ANCAs,	 the	 association	 of	GPA	with	 granulomatous	 inflammation	 and	 the	 risk	 of	






































PR3	 induces	 apoptosis	 of	 endothelial	
cells	
	

















approach	 studies	 led	 to	 the	discovery	of	 several	 other	 significant	 risk	 loci	 in	 autoimmune	
diseases	 such	 as	NOD2	 (275,	 276),	 IL2RA	 (277,	 278),	 PTPN22	 (144)	 and	CTLA4	 (279).	 The	
genetic	landscape	subsequently	changed	tremendously	following	the	emergence	of	GWAS	in	
2006	 where	 hundreds	 and	 thousands	 of	 risk	 loci	 were	 discovered	 over	 the	 last	 decade,	
revealing	the	polygenetic	basis	of	common	diseases	and	implicating	that	both	adaptive	and	
innate	immune	systems	play	a	major	role	in	the	pathogenesis	of	many	autoimmune	diseases,	
which	 translates	 into	 new	 therapeutic	 possibilities.	 For	 example,	 GWAS	 discoveries	 have	
sparked	 drug	 repurposing	 of	 biological	 medications	 targeting	 components	 of	 the	 IL-23	




GWAS	 is	a	powerful	 tool	which	utilises	hypothesis-free	and	 rigorous	 statistical	 association	





500K	SNPs	which	are	 carefully	 selected	 to	 capture	a	 sufficient	proportion	of	 the	 common	
variations	 in	 the	 genome,	 enabling	 the	 identification	 of	 loci	 associated	 with	 disease.	
Moreover,	GWAS	of	different	cohorts	can	be	combined	 into	a	meta-analysis	despite	being	






coverage	 of	 genetic	 variation	 across	 the	 genome	 without	 the	 need	 for	 resequencing	 or	
genotyping,	but	 is	 restricted	 to	 the	variants	 that	are	available	 in	 the	 reference	panel.	The	
HapMap	 reference	 set	 contains	 samples	 that	 have	 been	 genotyped	 on	 two	 different	
platforms,	the	Perlegen-Affymetrix	Human	SNP	Array	6.0	and	the	Illumina	Human	1M-single	
BeadChip.	The	data	set	consists	of	1,184	samples	from	11	populations	typed	up	to	2.5	million	
SNPs.	 In	 the	 1000	Genomes	 Project	 (phase	 3),	 the	 genomes	 of	 2,504	 individuals	 from	26	
populations	have	been	reconstructed	using	a	combination	of	 low-coverage	whole-genome	
sequencing,	deep	exome	 sequencing	and	dense	microarray	genotyping	 (285).	Overall,	 the	
existing	HapMap	and	1000	Genomes	Project	reference	panels	are	characterised	by	a	relatively	
small	sample	size	and	for	low-frequency	variants,	a	given	genotype	may	not	be	represented	
adequately	 in	 the	 reference	 data	 set.	 More	 recently,	 a	 new	 reference	 panel	 from	 the	
Haplotype	Reference	Consortium	(HRC)	has	become	available,	consisting	of	64,976	human	















broad	 sense	 refers	 to	 the	proportion	of	 the	phenotypic	 variance	due	 to	 genetic	 variance,	
which	can	be	further	divided	into	three	components:	additive	(average	effect	of	substituting	




dizygotic	 twins.	Despite	 the	 success	 in	 identifying	SNPs	 that	affect	 the	variation	 in	human	





and	to	challenge	the	“common	disease,	common	variant”	hypothesis	 (288)	 that	 forms	the	
initial	basis	of	GWAS,	predicting	that	the	genetic	component	of	complex	diseases	is	the	sum	
of	the	effects	of	common	or	frequent	genetic	variants.	Much	of	the	speculation	has	focused	
on	 the	 “common	 disease,	 rare	 variant”	 hypothesis,	 which	 argues	 that	 rare	 variants	 with	
relatively	 high	 penetrance	 (289)	 are	 the	 major	 contributors	 of	 the	 genetic	 component	
explaining	the	observed	phenotypic	variation	in	the	population.	The	strongest	argument	in	
favour	 of	 the	 rare	 allele	model	 comes	 from	 evolutionary	 theory	 where	 variants	 that	 are	
deleterious	 to	 fitness	 should	 be	 selected	 against	 and	 therefore	 should	 not	 be	 common.	
Pritchard	argued	 that	 the	 selection	processes	 such	as	mutation,	 random	genetic	drift	 and	
purifying	 selection	 against	 susceptibility	 mutations	 have	 acted	 on	 the	 human	 population	
during	 its	expansion	over	the	 last	few	centuries	and	have	led	to	multiple,	very	recent	rare	
variations	 contributing	 to	 disease	 that	 are	 mildly	 deleterious	 but	 not	 subjected	 to	 overt	
negative	selection	for	a	long	time,	hence	reaching	an	appreciable	frequency	and	exhibiting	
extensive	allelic	heterogeneity	(290).	Furthermore,	several	rare	structural	variants	have	been	
identified	 to	 confer	 a	 substantial	 risk	 to	 autism,	 mental	 retardation,	 epilepsy	 and	
schizophrenia	 (172).	On	 the	 contrary,	Hunt	 et	 al	 performed	deep	exon	 sequencing	 for	 25	
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common	 variants	 across	 the	 entire	 allele	 frequency	 spectrum	 contribute	 to	 the	 genetic	

















variation	 being	 the	 result	 of	 the	 combination	 of	 genotype-by-genotype	 interactions	
(epistasis),	genotype-by-environment	interactions	and	epigenetic	effects	(300,	301)	and	the	
“threshold	dependent	model”	which	posits	 that	 complex	disease	 is	more	 likely	 to	arise	 in	
individuals	who	have	extreme	values	of	multiple	intermediate	phenotypes	that	are	involved	
in	 the	 disease	 pathogenesis	 and	 often,	 each	 of	 these	 intermediate	 phenotypes	 has	 a	
component	 of	 genetic	 inheritance	 that	might	 not	 be	 detectable	 at	 the	 level	 of	 the	main	
complex	trait	(302).	The	missing	heritability	could	be	at	least	partly	attributed	to	the	sum	of	









intermediate	 phenotype	 with	 an	 outcome,	 by	 using	 the	 SNPs	 associated	 with	 the	
intermediate	phenotype.	An	example	of	successful	application	of	MR	analysis	in	autoimmune	













as	 the	 most	 likely	 causal	 gene	 but	 the	 physical	 distance	 of	 a	 variant	 to	 a	 gene	 is	 not	 a	
compelling	evidence	of	causality.	With	the	availability	of	big	data	derived	from	large	consortia	
and	 cohorts,	 advanced	 molecular	 technologies	 including	 single-cell	 genomics	 and	 new	
computational	 and	 statistical	 methods,	 a	 transformative	 era	 has	 begun	 to	 provide	
opportunities	to	bridge	this	existing	knowledge	gap.	This	process	can	be	broadly	divided	into	
two	main	stages:	(i)	fine	mapping	of	candidate	causal	variants	and	(ii)	 linking	the	potential	













simple	 approach	 is	 to	 consider	 all	 SNPs	with	 a	 p-value	 less	 than	 a	 certain	 threshold	 (e.g.	
standard	genome-wide	significant	threshold	of	5	x	10-8),	as	candidates	for	causality.	This	is	
hardly	sensible	as	p-values	are	influenced	by	study-specific	factors	such	as	power,	which	is	in	
turn	 determined	 by	 sample	 size	 and	 locus-specific	 factors	 such	 as	minor	 allele	 frequency	
(MAF)	and	effect	size.	Therefore,	such	a	threshold	is	not	directly	comparable	between	studies.	
A	 slightly	 more	 sophisticated	 method	 involves	 considering	 all	 SNPs	 above	 a	 certain	 LD	
threshold	with	the	lead	SNP	as	potential	causal.	Although	this	is	less	arbitrary	than	p-value	
thresholds,	 it	 still	 ignores	 the	 properties	 of	 the	 dataset.	 An	 alternative	 approach	 is	 the	








harnesses	 the	 different	 LD	 structures	 from	 ethnically	 diverse	 populations.	 For	 example,	 a	
genome-wide	trans-ancestry	meta-analysis	was	performed	using	MANTRA	in	type	2	diabetes	
comprising	 of	 26,488	 cases	 and	 83,964	 controls	 from	 European,	 east	 Asian,	 south	 Asian,	
Mexican	 and	 Mexican	 American	 ancestry,	 demonstrating	 considerable	 improvements	 in	
refining	 the	 association	 signals	 in	 several	 susceptibility	 loci	 –	 the	 greatest	 change	 was	





fraction	 of	 GWAS	 hits.	 Several	 large	 efforts	 such	 as	 the	 ENCODE	 (Encyclopedia	 of	 DNA	
Elements)	 (310),	 BLUEPRINT	 (311),	 ROADMAP	 (312)	 and	 FANTOM	 (313)	 consortia	 have	
greatly	 transformed	 our	 understanding	 of	 the	 roles	 of	 the	 noncoding	 genome	 and	 the	
mechanisms	underpinning	variation	in	gene	expression	in	various	cell	types,	by	facilitating	the	
functional	 annotation	 of	 the	 genome	 including	 mapping	 of	 post-translational	 histone	
modifications,	 transcription	 factor	 binding	 sites,	 CpG	 methylation	 and	 areas	 of	 open	





disease	 associated	 SNP	 in	 the	 super-enhancers,	 which	 are	 defined	 by	 large	 clusters	 of	
transcriptional	 enhancers	 that	 regulate	 spatiotemporal	 gene	 expression	 and	 define	 cell	
identity	 (315,	 316).	 Other	 public	 data	 resources	 such	 as	 the	 Genotype-Tissue	 Expression	
(GTEx)	project	(317)	and	whole	blood	analyses	(http://www.eqtlgen.org/cis-eqtls.html)	have	
been	 extremely	 useful	 in	 generating	 and	 compiling	 the	 expression	 quantitative	 trait	 loci	
(eQTL)	 data	 for	 a	 large	 of	 cohort	 of	 individuals	 in	 multiple	 tissues	 under	 many	 different	
conditions	(318).	However,	the	challenge	remains	in	autoimmune	diseases	whereby	there	is	
paucity	 of	 eQTL	 studies	 in	 purified	 immune	 cell	 types.	 Recent	 advances	 in	 proteomic	
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associated	 SNPs	 and	 the	 promoters	 of	 target	 genes,	 thus	 activating	 or	 repressing	
















Taken	 all	 together,	 these	 approaches	 complement	 the	 statistical	 methods.	 Each	 disease-
related	region	in	the	genome	can	be	fine	mapped	to	obtain	a	credible	set	of	causal	variants.	

































The	 study	 design	was	 conceived	 by	 the	 European	 Vasculitis	 Genetics	 Consortium	 (EVGC).	
Cases	 and	 controls	 were	 ascertained	 through	 the	 EVGC,	 Wellcome	 Trust	 Case	 Control	












I	 included	subjects	 from	two	European	ancestry	cohorts	as	described	 in	Table	2.1.	Briefly,	
GWAS1	was	the	discovery	cohort	from	Lyons	et	al	with	control	data	from	the	WTCCC.	The	










performed	 using	 the	 Sequenom	 MassARRAY	 platform.	 The	 study	 was	 approved	 by	 the	




Meta-analysis	 Cohort	 Genotyping	platform	 ‡Cases	 ‡Controls	
Stage	1	 †GWAS1	 Affymetrix	SNP6	 914	 5,259	
§GWAS2	 UK	Biobank	Axiom	array	 1,738	 6,688	














































612,676	 passed	 QC	 analysis.	 In	 addition,	 four	 SNPs	 were	 genotyped	 using	 TaqMan	 SNP	
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ensure	 downstream	 good	 quality	 genome-wide	 imputation	 of	 variants	 that	 are	 common	
(MAF	>	5%)	or	low-frequency	(MAF	=	1-5%).	The	exome	component	includes	over	130,000	
predominantly	rare	variants	and	was	designed	using	data	from	three	large	exome	sequencing	
projects:	 the	 NHLBI	 Exome	 Sequencing	 Project	 (ESP)	 (324),	 the	 Exome	 Aggregation	
Consortium	(ExAC)	(325)	and	the	UK10K	non-Finnish	project	(326).	Additional	rare	variants	
were	included	in	cardiac	disease	and	cancer	predisposition	genes,	as	well	as	other	variants	




on	 the	 array	 includes	 markers	 that	 are	 disease	 specific,	 including	 markers	 related	 to	
Alzheimer’s,	 autoimmune	 and	 inflammatory,	 blood	phenotypes,	 cancers,	 cardiometabolic,	
neurological	disease	as	well	as	dense	coverage	of	selected	genomic	regions	such	as	ApoE,	
HLA,	killer-cell	immunoglobulin-like	receptor,	Y	chromosome	and	mitochondria.	Of	particular	




For	 GWAS2,	 genotype	 calling	 was	 performed	 using	 the	 Affymetrix	 Powertools	 software.	
Calling	was	performed	in	batches	of	contemporaneously	run	plates	as	per	the	manufacturer’s	
protocol.	After	genotype	calling,	 SNP	data	was	processed	 in	 the	 following	 sequence	using	
PLINK	v1.9	(329).	Samples	with	proportion	of	missing	SNPs	>	5%,	sex	mismatch	or	abnormal	
heterozygosity	were	removed.	SNPs	with	a	genotyping	call	rate	<	98%,	deviation	from	Hardy-
Weinberg	Equilibrium	 (p	<	1	 x	10-6)	or	monomorphic	were	 removed.	The	QC	process	was	
performed	 separately	 for	 each	 batch.	 The	 post-QC	 genotype	 data	 from	 each	 batch	 was	
subsequently	merged.	Duplicated	or	related	samples	(identified	using	Identity	by	State)	were	
removed	and	the	SNP	QC	was	performed	again	so	that	SNPs	with	a	genotype	call	rate	<	98%	
or	 deviation	 from	 Hardy-Weinberg	 Equilibrium	 (p	 <	 1	 x	 10-6)	 in	 the	 combined	 data	 were	
excluded.	SNPs	that	showed	significant	differential	missingness	(p	<	1.0	x	10-5)	between	cases	

















plink	 --pca	 containing	 both	 cases	 and	 controls	 and	 included	 as	 covariates	 to	 adjust	 for	
potential	 confounding	 and	 population	 substructures.	 Although	 this	 traditional	 genomic	
control	approach	(330)	carries	a	small	risk	of	masking	true	disease	associations,	it	is	a	more	
appropriate	 test	 given	 (i)	 the	 UK	 controls	 were	 genotyped	 in	 a	 different	 facility	 thereby	
potentially	 leading	 to	 confounding	 from	 a	 batch	 effect	 and	 (ii)	 French	 controls	 were	 not	
included	in	GWAS2.	I	also	tested	the	effect	of	using	increasing	numbers	of	PCs	as	covariates	
on	the	genomic	inflation	factor	(lambda,	λ)	which	is	the	ratio	of	the	median	of	the	observed	








the	population	mean	at	each	variant	 in	 the	data	set	and	compares	 individuals	pairwise	 to	





traits	 simply	by	 treating	 the	binary	 trait	 as	a	quantitative	 trait	with	 the	 caveat	 that	 it	 can	
become	miscalibrated	for	unbalanced	case-control	traits	resulting	in	false	positive	association	
at	 rare	 SNPs.	 Moreover,	 a	 transformation	 of	 the	 effect	 size	 estimates	 (beta,	 b)	 on	 a	












Michigan	 Imputation	Server	v1.0.3	 that	 facilitates	access	 to	the	HRC	reference	panel	 (HRC	


























Chromosome	 Imputation	output	 Filter	at	R2	0.3	 Imputation	output	 Filter	at	R2	0.3	
1	 3,069,931	 587,094	 3,069,931	 593,584	
2	 3,392,237	 644,689	 3,392,237	 650,354	
3	 2,821,894	 548,655	 2,821,894	 551,007	
4	 2,787,581	 559,243	 2,787,581	 563,826	
5	 2,588,168	 500,249	 2,588,168	 502,202	
6	 2,460,111	 510,367	 2,460,111	 515,160	
7	 2,289,305	 447,339	 2,289,305	 453,673	
8	 2,242,705	 428,952	 2,242,705	 432,423	
9	 1,675,898	 328,463	 1,686,471	 333,220	
10	 1,927,503	 390,344	 1,927,503	 393,635	
11	 1,936,990	 381,881	 1,936,990	 385,876	
12	 1,848,117	 369,942	 1,848,117	 372,997	
13	 1,385,433	 286,914	 1,385,433	 288,391	
14	 1,266,536	 251,658	 1,270,436	 255,973	
15	 1,139,215	 218,634	 1,139,215	 220,353	
16	 1,281,297	 233,729	 1,281,297	 239,615	
17	 1,090,072	 199,069	 1,090,072	 204,325	
18	 1,104,755	 222,763	 1,104,755	 223,483	
19	 868,554	 160,528	 868,554	 174,381	
20	 884,983	 174,108	 884,983	 175,283	
21	 531,276	 106,992	 531,276	 108,140	
22	 524,544	 104,963	 524,544	 106,633	
Totals	 39,117,105	 7,656,576	 39,131,578	 7,744,534	
	





















HLA-DPA1	 and	 HLA-DPB1)	 from	 phased	 genotype	 data	 using	 the	 HLA*IMP:03	 software	










GCTA	 (option	 ‘--pca	 20’)	 were	 included	 as	 covariates	 in	 the	 model	 when	 estimating	 the	
genetic	variance	explained	by	all	the	SNPs	on	the	observed	scale.	As	the	studied	phenotypes	

















between	 PR3-AAV	 and	 MPO-AAV	 was	 estimated	 using	 the	 bivariate	 linear	 mixed-effects	
model	implemented	in	GCTA	(339).	This	method	uses	genome-wide	SNPs	to	estimate	genetic	
















LD.	 There	 are	 few	 ways	 to	 define	 approximately	 independent	 LD	 blocks	 including	 non-





























Colocalisation	 analysis	 was	 performed	 using	 the	 ‘coloc’	 R	 package	 to	 evaluate	 whether	
intermediate	cellular	phenotypes	(e.g.	eosinophil,	neutrophil	and	monocyte	counts)	and	AAV	
share	 the	 same	 causal	 variant	 at	BCL2L11	 locus.	 Summary	 statistics	were	obtained	 for	 all	
variants	within	the	LD-defined	haplotype	region	for	peripheral	blood	eosinophil,	neutrophil	
and	monocyte	counts	 in	a	population	 study	by	Astle	et	al	 (346).	A	 total	of	5,505	of	 these	
variants	 was	 available	 in	 the	 AAV	 dataset.	 The	 posterior	 probabilities	 of	 different	 causal	
variant	configurations	were	calculated	under	 the	assumption	of	a	single	causal	variant	 for	










randomised	 controlled	 trials	 to	 examine	 the	 causality	 are	 not	 feasible	 and	 observational	
studies	provide	biased	associations	because	of	confounding	or	reverse	causality.	MR	analysis	
is	an	alternative	of	randomised	trial,	exploiting	the	random	allocation	of	alleles	at	birth	to	
allow	 causal	 inference.	 The	 choice	 of	 a	 genetic	 instrumental	 variable	 is	 essential	 to	 a	
successful	MR	study.	In	order	to	achieve	an	unbiased	estimation	of	the	causal	effect	of	the	









MR	 analysis	 was	 performed	 using	 the	 ‘MendelianRandomization’	 R	 package.	 Summary	
statistics	including	beta	coefficient	and	standard	error	of	the	variants	were	obtained	from	a	

















It	 is	 well	 established	 that	 DNA	 regulatory	 elements	 such	 as	 enhancers	 or	 insulators	 can	
regulate	 gene	 transcription	 by	 physically	 interacting	with	 their	 target	 gene	 promoters	 via	
looping	 of	 DNA,	 which	 are	 both	 cell-type	 and	 stimulus	 specific.	 Long-range	 interactions	
between	genetic	 variants	 associated	with	AAV	and	gene	promoter	and	 regulatory	 regions	
were	identified	using	the	promoter	capture	Hi-C	datasets	from	a	wide	range	of	primary	cell	





Other	 diseases	 and	 traits	 associated	 with	 AAV-associated	 loci	 were	 identified	 using	
PhenoScanner	 v2	 (350).	 PhenoScanner	 is	 a	 curated	 database	 containing	 over	 65	 billion	
association	results	from	multiple	sources	including	the	NHGRI-EBI	(National	Human	Genome	






datasets	 including	 the	 GTEx	 and	 BIOS	 Consortium,	 with	 a	 total	 of	 31,684	 individuals.	
Functional	annotation	was	performed	using	FUMA	(351)	–	an	integrative	web-based	platform	
that	 facilitates	 functional	 annotation	 of	 GWAS	 results,	 gene	 prioritisation	 and	 interactive	
visualisation	 using	 information	 from	 18	 biological	 resources	 comprising	 of	 functional	
annotations	of	SNPs	(CADD	v1.3,	RegulomeDB,	15-core	chromatin	state	and	GWAS	catalog),	













Dr	 Elaine	 Jolly.	 The	 initial	 sample	 processing	 was	 performed	 at	 the	 Smith	 Laboratory	 by	
several	clinicians	and	lab	assistants	depending	on	availability	and	resources.	I	was	primarily	
involved	 in	 DNA/RNA	 extraction	 and	 processing	 RNA	 samples	 for	 Affymetrix	 whole	
transcriptome	 microarray	 analysis	 as	 well	 as	 RNA	 sequencing	 for	 the	 ESKD	 cohort.	







observational	 study	 of	 gene	 expression	 patterns	 in	 autoimmune	 disease.	 Inpatients	 and	
outpatients	fulfilling	the	criteria	according	to	the	EMEA	or	CHCC	nomenclature	were	referred	
by	 clinicians	 of	 the	 service	 and	 enrolled	 prior	 to	 receiving	 induction	 immunosuppression.	
Initial	 ethical	 approval	 for	 recruitment	 and	 its	 extension	were	 obtained	 by	 Professor	 Ken	
Smith	 from	 the	National	 Research	 Ethics	 Service	 Committee	 East	 of	 England	 -	 Cambridge	
Central	 (ref:	 08/H0308/176	 and	 08/H306/21).	 Patients	 provided	 60-100	 ml	 of	 peripheral	
venous	blood	through	a	21-gauge	needle	at	3	time	points:	(i)	flaring	disease:	at	recruitment,	
prior	to	induction	therapy;	(ii)	early	remission:	3	months	after	recruitment	usually	towards	















and	 recalled	 from	 the	 database	 of	 the	 ongoing,	 prospective	 observational	 study	 of	 gene	
expression	patterns	in	autoimmune	diseases.	A	total	of	100	ml	of	peripheral	venous	blood	











cell	 activation.	 Ethical	 approval	 was	 granted	 by	 the	 National	 Research	 Ethics	 Service	
Committee	East	of	England	-	Cambridge	Central	(ref:	08/H0308/176).	A	total	of	16	individuals	
were	 recruited	 and	 matched	 pair	 experiments	 were	 carried	 out	 to	 reduce	 possible	







Blood	 samples	 were	 processed	 immediately	 to	 prevent	 any	 transcriptional	 alterations,	
especially	 in	 cells	 from	 the	myeloid	 lineage.	 Individual	 leukocyte	 subsets	were	purified	 as	





Human	 peripheral	 blood	 neutrophils	 were	 purified	 from	 peripheral	 blood	 using	 Percoll	
gradient	as	previously	described	(353).	Briefly,	the	collected	blood	was	centrifuged	at	300	g	
for	20	min,	acceleration	9,	brake	3	at	24°C.	Post-centrifugation,	two	layers	were	formed:	a	












supernatant	 (myeloid	 cells	 enriched)	was	 observed.	 The	myeloid	 cells	 enriched	 layer	was	
removed	into	a	fresh	50	ml	falcon	tube	and	centrifuged	at	260	g	for	5	min,	acceleration	9,	

















5	 x	 106	 cells/ml	 supplemented	with	 10%	 autologous	 serum,	 100	 U/mL	 penicillin	 and	 100	
µg/mL	streptomycin	and	cultured	in	a	humidified	5%	CO2	atmosphere	at	37°C	in	the	presence	
and	absence	of	predetermined	optimal	concentrations	of	granulocyte-macrophage	colony-
stimulating	 factor	 (GM-CSF,	 10	 ng/ml)	 for	 6	 hr	 and	 20	 hr.	 Neutrophils	were	 harvested	 at	
different	time	points	and	resuspended	in	RLT	buffer	with	1%	b-mercaptoethanol	and	stored	
at	 -80°C	 for	 future	 RNA	 extraction.	 Cell	 purities	 were	 assessed	 by	 using	 air-dried	





Human	peripheral	blood	eosinophils	were	purified	using	 the	RoboSepä	 cell	 separation	kit	















mixture.	 Cell	 counting	 was	 performed	 using	 a	 haemocytometer	 (red	 blood	 cells	 were	
excluded	from	the	counting).	The	cell	mixture	was	centrifuged	again	for	10	min,	acceleration	
9,	brake	9	at	24°C.	 The	 cell	 pellet	was	 then	 resuspended	 in	RoboSepä	 buffer	 at	50	 x	106	
cells/ml.	 Finally,	 the	 sample	 was	 placed	 in	 RoboSepä	 Automated	 Cell	 Separator	 and	 the	
separation	took	approximately	30-40	min.	Post-RoboSep,	cell	counting	was	performed.	The	
























Eosinophils	 were	 cultured	 in	 a	 final	 volume	 of	 150	 µl	 in	 flat-bottomed	 96-well,	 ultralow	
attachment	plates	(Costar,	Hycombe,	Bucks,	UK)	for	24	hours.	Following	resuspension,	the	
cells	 were	 aspirated,	 cytocentrifuged,	 fixed	 and	 stained	 as	 described	 in	 section	 2.2.5.3.	
Morphologic	 analysis	 of	 eosinophil	 apoptosis	 was	 assessed	 under	 oil	 immersion	 light	
microscopy	with	the	observer	masked	to	the	experimental	conditions.	Apoptotic	eosinophils	
were	defined	as	cells	with	darkly	stained,	condensed	nuclei	 (Figure	2.6).	A	more	objective	






















































Mastercyclerâ	 Nexus	 for	 reverse	 transcription	 (RT)	 with	 the	 following	 thermal	 cycling	












































































membranes	were	washed	3	times	 in	TBST	for	10	min	on	a	rocker	prior	 to	 incubation	with	
species-specific	HRP-conjugated	secondary	antibody	(Cell	Signaling	Technology®)	at	1:10,000	
dilution	for	45	min	at	room	temperature.	Membranes	were	then	washed	again	for	3	times	in	
TBST	 and	 once	 in	 PBS	 before	 being	 developed	 with	 SuperSignal™	 West	 Pico	 PLUS	
Chemiluminescent	Substrate	or	SuperSignal™	West	Femto	Maximum	Sensitivity	Substrate	as	




cDNA	was	 synthesized	 and	 amplified	 from	 total	 RNA	using	 the	Ambionâ	whole	 transcript	














Fragmented	 DNA	 was	 labelled	 by	 terminal	 deoxynucleotidyl	 transferase	 (TdT)	 covalently	















Bioanalyzer	DNA	high	sensitivity	kit	 (Agilent)	prior	 to	 library	quantification	using	the	KAPA	
Illumina	Sequencing	Library	qPCR	Quantification	kit.	All	19	 libraries	were	pooled	to	a	 final	
concentration	of	4nM.	Sequencing	of	the	prepared	libraries	was	conducted	at	the	Cambridge	
Genomic	 Services,	 Department	 of	 Pathology,	 University	 of	 Cambridge	 using	 the	 Illumina	





















Human	 neutrophils	 were	 purified	 from	 the	 peripheral	 blood	 of	 heterozygous	 healthy	
volunteers	 as	 described	 in	 sections	 2.2.5.2.	 Freshly	 isolated	 neutrophils	 were	 routinely	
suspended	 at	 5	 x	 106/mL	 in	 IMDM	supplemented	with	 10%	autologous	 serum,	 100	U/mL	
penicillin	 and	 100	 µg/mL	 streptomycin.	 They	 were	 cultured	 in	 a	 humidified	 5%	 CO2	





RLT	 plus	 buffer.	 gDNA	 and	 RNA	 were	 extracted	 from	 the	 lysates	 using	 Qiagenâ	 AllPrep	
DNA/RNA	Mini	kit.	RNA	was	treated	with	TURBO™	DNase	(Thermo	Fisher	Scientific)	to	ensure	
complete	 removal	 of	 gDNA	 from	 the	 samples	 and	 reversed	 transcribed	 to	 cDNA	 using	





bp)	 were	 gel-purified	 and	 sequenced	 using	 the	 Sanger	 method	 to	 confirm	 the	 sequence	
variant.	 The	 amplicons	 were	 then	 cloned	 into	 pCRä-Blunt	 II-TOPOÒ	 vectors	 containing	 a	



































the	 robust	 multichip	 average	 method.	 QC	 was	 performed	 using	 the	 arrayQualityMetrics	
package.	 The	 parameters	 that	 were	 assessed	 as	 part	 of	 this	 QC	 process	 included	 array	
intensity	 distributions,	 between	 array	 distance	 comparisons,	 individual	 array	 quality	 and	
standard	deviation	versus	rank	of	the	mean.	An	object	(“exprsFile”)	was	generated	containing	
QC	 and	 normalised	 microarray	 data	 of	 x	 number	 of	 patients.	 Following	 the	 initial	 pre-
processing	 steps,	 an	 ExpressionSet	 was	 created	 using	 the	 Biobase	 package,	 consisting	 of	
expression	data	 from	microarray	 experiments	 (assayData,	 a	matrix	 of	 “expression”	 values	
which	has	F	rows	and	S	columns,	where	F	is	the	number	of	features	on	the	chip	and	S	is	the	
number	 of	 samples),	 phenotypic	 data	 describing	 samples	 in	 the	 experiment	 (phenoData),	
annotations	 and	 meta-data	 about	 the	 features	 on	 the	 chip	 used	 for	 the	 experiment	
(featureData,	Affymetrix	 human	gene	1.1	 ST	 array	 annotations	which	 contain	 information	
such	as	gene	name,	symbol,	Entrez	ID	or	chromosomal	location).	The	ExpressionSet	class	is	





























































with	 HISAT2	 using	 the	 Genome	 Reference	 Consortium	 Human	 Build	 38	 (GRCh38).	 QC	 of	





























were	 performed	 using	 the	 Kruskal-Wallis	 rank-sum	 test.	 Where	 the	 comparison	 was	
significant,	 pairwise	 two-sample	 Wilcoxon	 tests	 were	 performed	 to	 determine	 which	





































































4.9	 per	million	 per	 year	 (32).	 PR3-AAV	 patients	 are	more	 likely	 to	 have	 upper	 and	 lower	
respiratory	tract	as	well	as	renal	involvement	as	opposed	to	vasculitis	limited	to	the	kidneys	
in	MPO-AAV.	The	nature	of	pulmonary	involvement	differs	between	ANCA	serotypes	where	






identified	 two	 genome-wide	 significant	 loci	 at	 SERPINA1	 (chr14q32.13)	 and	 PRTN3	
(chr19p13.3)	to	be	associated	with	PR3-AAV.	In	order	to	identify	additional	risk	loci	associated	
with	 PR3-AAV,	 a	 total	 of	 1,132	 PR3-AAV	 cases	 from	 Europe,	 along	with	 6,688	 population	
matched	 controls,	 were	 genotyped	 on	 the	UK	 Biobank	 Axiom	 array.	 A	meta-analysis	was	
subsequently	performed	with	the	recent	AAV	GWAS	by	Lyons	et	al	(70).	
	






























remained	 over	 1.1	 despite	 fitting	 an	 increasing	 number	 of	 PCs	 as	 covariates	 in	 a	 linear	



















































Two	 previously	 reported	 genome-wide	 significant	 non-HLA	 risk	 loci	 were	 replicated,	
rs112635299	at	chr14q32.13	(SERPINA1)	and	rs55952682	at	chr19p13.3	(PRTN3).	Although	

























†OR	(95%	CI)	  yP	 †OR	(95%	CI)	 yP	 †OR	(95%	CI)	  DP	
rs115670873	 2p13.1	 74,171,061	 DGUOK,	TET3	 A	 0.93	 1.11	(0.70-1.78)	 6.50	X	10-1	 1.72	(1.48-2.00)	 8.60	X	10-12	 1.68	(1.44-1.97)	 1.22	X	10-10	
rs13405741	 2q13	 111,913,056	 BCL2L11,	
MIR4435-2HG	
C	 0.11	 1.55	(1.20-1.99)	 6.60	X	10-4	 1.34	(1.17-1.53)	 1.60	X	10-5	 1.40	(1.24-1.58)	 3.76	X	10-8	
rs3130216	 6p21.32	 33,077,271	 HLA-DP	 G	 0.48	 3.06	(2.68-3.49)	 1.50	X	10-61	 2.46	(2.28-2.65)	 4.30	X	10-114	 2.58	(2.41-2.75)	 3.59	X	10-173	
rs145007430	 10q26.3	 131,690,291	 EBF3,	MGMT	 A	 0.02	 4.75	(2.50-9.04)	 2.00	X	10-6	 1.77	(1.26-2.49)	 5.70	X	10-4	 2.39	(1.76-3.25)	 2.38	X	10-8	
rs112635299	 14q32.13	 94,838,142	 SERPINA1	 T	 0.02	 6.51	(4.21-10.07)	 4.20	X	10-17	 2.56	(1.99-3.30)	 8.90	X	10-13	 3.43	(2.75-4.27)	 2.37	X	10-28	
rs11845244	 14q32.33	 107,170,077	 IGHV1-69	 T	 0.37	 1.29	(1.12-1.49)	 4.70	X	10-4	 1.21	(1.11-1.32)	 2.00	X	10-5	 1.23	(1.15-1.33)	 2.16	X	10-8	




















evidence	 from	 experimental	 literature	 and	 other	 genomic	 databases	 to	 provide	 further	

















myeloid	 progenitor	 and	 haematopoietic	 stem	 cells	 (BLUEPRINT	 data	 release	 2016-08).	
Mutations	 in	 this	 gene	 has	 been	 associated	 with	 mitochondrial	 DNA	 (mtDNA)	 depletion	
syndrome	 (OMIM:251880)	where	affected	 individuals	 suffer	 from	progressive	 liver	 failure,	
		
	82	
neurological	 abnormalities,	 hypoglycaemia	 and	 increased	 lactate	 in	 body	 fluids.	 However,	
immune	phenotypes	have	not	been	reported.	Affected	tissues	were	previously	shown	to	have	
decreased	activity	of	the	mtDNA-encoded	respiratory	chain	complexes	(I,	III,	IV,	V)	and	mtDNA	









most	 abundantly	 in	 the	 myeloid	 and	 monocytic	 haematopoietic	 cells,	 and	 it	 has	 been	





was	 independent	 of	 DNA	 demethylation,	 instead	 TET3	 recruited	 histone	 deacetylase	 1	
(HDAC1)	 to	 the	 promoter	 of	 IFNB1	 (366).	 In	 addition,	 global	 hypomethylation	 has	 been	
observed	in	CD4+	T	cells	in	individuals	with	SLE	and	it	has	been	postulated	that	demethylation	









the	 role	 of	 STAMBP	 in	 deubiquitinating	NALP7	 (NACHT,	 LRR	 and	 PYD	 domains-containing	
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protein	7)	which	 is	one	of	the	 inflammasome	constituents,	to	 impede	NALP7	trafficking	to	
lysosomes,	 leading	 to	 an	 increase	NALP7	 abundance	 and	 inflammasome-dependent	 IL-1b	
cleavage	 and	 release.	 A	 small-molecule	 inhibitor	 of	 STAMBP	 deubiquitinase	 activity,	
decreases	NALP7	protein	levels	and	suppressed	IL-1b	release	after	TLR	agonism,	suggesting	it	





































































rs145007430	 EBF3,	MGMT	 Intronic	 Atopic	eczema,	psoriasis	(377)	 In	proximity	 n/a	 n/a	 MGMT,	PTPRE	 n/a	
†RA	




















































































(ACOXL)	 (Figure	3.3).	Furthermore,	 rs13405741	 is	a	known	eQTL	 for	BCL2L11	 in	 the	whole	
blood	 with	 p-value	 of	 8.75	 x	 10-36,	 where	 the	minor	 allele	 (C,	 risk	 allele	 for	 PR3-AAV)	 is	
associated	with	a	higher	expression	of	BCL2L11,	supporting	that	the	SNP	might	play	a	role	in	
regulating	the	expression	of	BCL2L11	(318).	In	addition,	BCL2L11tm1.1Ast	knockout	mice	exhibit	


















Top	 to	 bottom	panels:	Genomic	 positions	 (hg19),	 representative	RefSeq	 genes,	 PCHi-C	 data	 (Javierre	 et	 al	 -	



























regulatory	 region	 and	 the	 promoter	 region	 of	 O-6-methylguanine-DNA	methyltransferase	
(MGMT)	 in	GM12878	 cell	 line,	which	 encodes	 a	 protein	 that	 catalyses	 transfer	 of	methyl	
groups	 from	 O(6)-alkylguanine	 and	 other	 methylated	 moieties	 of	 the	 DNA	 to	 its	 own	
molecule.	Mechanistically,	DNA	methylation	can	modulate	gene	expression	by	influencing	the	
binding	 affinities	 of	 transcription	 factors.	 It	 was	 demonstrated	 that	 patients	 with	
hypersensitivity	 pneumonitis	 had	 evidence	 of	 hypomethylation	 of	 EBF3	 as	 compared	 to	
healthy	controls	with	significantly	higher	expression	of	EBF3,	 IL-4	and	IL-10,	 indicating	that	
EBF3	hypomethylation	in	B	cells	might	play	a	role	in	the	conversion	of	Th1	dominant	to	Th2	
dominant	 response	 in	 patients	 who	 were	 in	 the	 chronic	 phase	 of	 the	 disease	 (383).	 In	










Top	 to	 bottom	 panels:	 Genomic	 positions	 (hg19),	 representative	 RefSeq	 genes,	 PCHi-C	 data	 (Mifsud	 et	 al	 -	
GM12878	 cell	 line),	 SNPs	 association	 with	 PR3-AAV	 where	 the	 filled	 red	 circle	 indicates	 the	 lead	 SNP	















“Z”	 allele.	 The	 PCHi-C	 dataset	 showed	 interactions	 with	 the	 promoters	 of	 SERPINA5,	
SERPINA9,	SERPINA11	and	SERPINA12	in	GM12878	cell	line.	SERPINA5	encodes	for	protein	c	
inhibitor	 which	 interacts	 with	 lipid	 membrane	 leading	 to	 permeabilisation	 of	 bacterial	






Top	 to	 bottom	 panels:	 Genomic	 positions	 (hg19),	 representative	 RefSeq	 genes,	 PCHi-C	 data	 (Mifsud	 et	 al	 -	









is	 the	 last	 amino	 acid	 in	 the	 framework	 region	 2	 and	 is	 immediately	 adjacent	 to	 the	
complementarity	determining	region	2	(CDR2)	as	demonstrated	 in	Figure	3.7.	 It	 is	a	trans-














light	 chains	 (VL).	 The	 variable	 region	 of	 Ig	 that	 binds	 to	 the	 antigen	 for	which	 the	 antibody	 is	 specific	 to	 is	
highlighted	 in	 a	 red	 dotted	 circle.	 Each	 heavy	 and	 light	 chain	 contains	 three	 complementarity-determining	
regions	(CDRs)	that	are	folded	together	to	form	the	antigen	binding	site,	which	determine	the	specificity	and	the	
affinity	of	binding.	rs11845244	is	a	missense	variant	that	results	in	a	change	of	amino	acid	at	position	50	from	
glycine	 to	 arginine	 (G50R),	which	 is	 located	 at	 the	 border	 of	 framework	 region	 2	 of	 the	 heavy	 chain	 and	 is	
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indicated	 by	 a	 filled	 red	 circle.	 The	 rearranged	 genomic	 VH1-69	 gene	 encoding	 the	 protein	 heavy	 chain	 is	
demonstrated.	
(B)	 The	 amino	 acid	 sequences	 of	 IGHV1-69	 alleles	 are	 aligned	 and	 grouped	 based	 on	 the	 occurrence	 of	
phenylalanine	or	leucine	at	position	54	(F54L).	The	black	boxes	highlight	the	location	of	CDR1,	CDR2	and	partial	
CDR3	based	on	the	 International	 Immunogenetics	 Information	System	(IMGT)	database.	Positions	where	the	
alleles	are	different	among	the	sequences	are	depicted	with	colored	amino	acids.		
(C)	The	genotype	frequency	differences	at	two	SNPs	in	IGHV1-69	that	have	been	shown	to	encode	functional	
residues	 that	 are	 critical	 for	 neutralizing	 antibodies	 against	 the	 influenza	 hemagglutinin	 stem	 region	
















the	 Fc	 region	 composed	 completely	 by	 an	 IGHC	 gene	 (385).	 Each	 heavy	 and	 light	 chain	
contains	 three	 CDRs	 that	 are	 folded	 together	 to	 form	 the	 antigen-binding	 site,	 which	
determine	the	specificity	and	the	affinity	of	binding.	Random	rearrangement	of	the	heavy-	
and	 light-chain	genes	 further	 increases	genetically	encoded	diversity	 to	ensure	 that	 it	will	
likely	 contain	 a	 naïve	 antibody	 with	 at	 least	 weak	 initial	 binding	 against	 a	 vast	 array	 of	
antigens.	This	diversity	will	then	be	augmented	following	antigen	stimulation	where	B	cells	

















importantly,	 using	 enzyme-linked	 immunosorbent	 assay,	 they	 also	 showed	 that	 allelic	
variation	at	position	50	(R50)	completely	abolished	NEAT2	binding,	presumably	due	to	steric	
hindrance	(394).	Both	rs55891010	and	rs11845244	are	in	high	LD	(r2	=	0.93)	and	therefore	
L54	and	R50	amino	acid	 tend	to	co-occur	 in	alleles	of	 IGHV1-69.	The	 frequencies	of	 these	
critical	alleles	vary	across	populations	where	the	L54	and	R50	amino	acids	are	most	commonly	






(pGWAS2	 =	 1.90	 x	 10-11),	 is	 located	 in	 the	 upstream	 region	 of	 PRTN3	 and	 downstream	 of	
azurocidin	1	(AZU1).	AZU1	encodes	a	protein	precursor	that	 is	proteolytically	processed	to	
generate	 a	 mature	 azurophil	 granule	 antibiotic	 protein	 with	 antimicrobial	 and	 monocyte	
chemotactic	activity.	AZU1,	neutrophil	elastase	2	(ELANE)	and	PRTN3	are	located	in	a	cluster.	
Their	mRNA	 expressions	 are	 coordinately	 controlled	 during	 neutrophil	 differentiation	 and	
their	protein	products	are	packaged	into	azurophil	granules.	The	lead	SNP	and	several	SNPs	



















Top	 to	 bottom	 panels:	 Genomic	 positions	 (hg19),	 representative	 RefSeq	 genes,	 PCHi-C	 data	 (Mifsud	 et	 al	 -	






	 *Lead	pQTLs	 *Conditionally	independent	pQTLs	 Lyons	et	al	 Merkel	et	al	 Present	study	












































































































































were	 imputed.	 Univariate	 LMM	 analysis	 identified	 nine	 HLA	 alleles	 conferring	 either	
susceptibility	or	protection	to	PR3-AAV.	To	test	association	among	imputed	HLA	alleles	and	
amino	acid	variants,	I	used	a	forward	stepwise	strategy	to	establish	statistically	independent	





HLA-DPB1*04:01-HLA-DQB1*06:02-HLA-DRB1*15:01,	 HLA-DPB1*04:02	 and	 HLA-DPA1*	
01:03-HLA-DPB1*02:01	 while	 the	 remaining	 signal	 conferred	 protection	 by	 an	 extended	
haplotype	 encoding	 HLA-DRB1*01:01-HLA-DQA1*01:01-HLA-DQB1*05:01.	 The	 strongest	
independent	associations	with	disease	susceptibility	were	observed	at	HLA-DPB1*04:01	(OR	
=	2.52,	 p	 =	 4.60	 x	 10-116),	HLA-DPB1*04:02	 (OR	=	2.47,	 conditional	 p	 =	 5.90	 x	 10-38),	HLA-











for	 most	 of	 the	 HLA	 allele	 effects	 (HLA-DQB1*06:02,	 conditional	 p	 =	 0.00054	 and	 HLA-





















OR	 P	 OR	 P	 OR	 P	 OR	 P	 OR	 P	
HLA-DPB1*04:01	 2.52	 4.6	x	10-116	 -	 -	 -	 -	 -	 -	 -	 -	
HLA-DPA1*01:03	 2.36	 2.9	x	10-54	 1.58	 7.1	x	10-14	 1.25	 3.6	x	10-5	 1.27	 2.4	x	10-5	 1.12	 0.036	
HLA-DPA1*02:01	 0.42	 1.7	x	10-44	 0.65	 6.6	x	10-11	 0.82	 1.1	x	10-3	 0.82	 1.0	x	10-3	 0.93	 0.20	
HLA-DPB1*03:01	 0.43	 4.8	x	10-32	 0.66	 1.4	x	10-7	 0.83	 0.054	 0.83	 0.045	 0.94	 0.80	
HLA-DPB1*01:01	 0.44	 8.1	x	10-18	 0.69	 1.7	x	10-4	 0.86	 0.10	 0.83	 0.042	 0.93	 0.38	
HLA-DPB1*02:01	 0.60	 1.8	x	10-15	 1.02	 0.54	 1.40	 9.4	x	10-7	 1.41	 3.5	x	10-7	 -	 -	
HLA-DPA1*02:02	 0.49	 7.1	x	10-9	 0.71	 5.1	x	10-3	 0.84	 0.086	 0.82	 0.065	 0.90	 0.23	
HLA-DQA1*01:01	 0.74	 8.2	x	10-9	 0.76	 1.2	x	10-7	 0.71	 1.2	x	10-10	 -	 -	 -	 -	
HLA-DQB1*06:02	 1.37	 1.7	x	10-8	 1.04	 0.41	 -	 -	 -	 -	 -	 -	
HLA-DRB1*15:01	 1.34	 9.2	x	10-8	 1.01	 0.62	 -	 -	 -	 -	 -	 -	
HLA-DQB1*05:01	 0.74	 2.1	x	10-7	 0.77	 8.0	x	10-6	 0.71	 2.1	x	10-9	 0.92	 0.51	 -	 -	
HLA-DRB1*01:01	 0.75	 3.3x	10-6	 0.80	 1.6	x	10-4	 0.71	 4.0	x	10-8	 0.92	 0.36	 -	 -	











In	 this	 study,	 seven	 risk	 loci	 for	 PR3-AAV	were	 identified.	We	 replicated	 three	 previously	
identified	 genome-wide	 significant	 risk	 loci	 including	 HLA-DP,	 SERPINA1	 and	 PRTN3.	
Additional	four	risk	loci	were	implicated	in	PR3-AAV	for	the	first	time.	Within	the	classical	HLA	
alleles,	 three	 independent	 signals	 were	 identified	 to	 confer	 disease	 risk,	 including	 HLA-
DPB1*04:01-HLA-DQB1*06:02-HLA-DRB1*15:01,	 HLA-DPB1*04:02	 and	 HLA-DPA1*01:03-
HLA-DPB1*02:01.	The	estimated	SNP	heritability	(h2SNP)	for	PR3-AAV	was	modest	(0.46	±	se	











section	 1.4.2.	 This	 locus	was	 reported	 in	 previous	 GWAS	 by	 EVGC	 and	 VCRC	 (albeit	 with	
different	 lead	 SNPs).	 The	 association	 was	 limited	 to	 the	 GPA	 and	more	 importantly,	 the	
association	 was	 stronger	 in	 the	 PR3-ANCA	 subset.	 Together	 with	 the	 eQTL	 and	 pQTL	





(also	 known	 as	 the	 “Z”	 allele,	 which	 is	 in	 complete	 LD	with	 the	 lead	 SNP,	 rs112635299).	





11),	 it	was	 found	 to	 be	 associated	with	 13	 proteins	 (trans-pQTL),	 supporting	 that	 a	 single	
mutation	can	cause	perturbation	of	a	wide	range	of	downstream	proteins	(319).	Interestingly,	
one	 of	 these	 proteins	 was	 neutrophil	 cytosolic	 factor	 2	 (NCF2),	 which	 is	 involved	 in	 the	
neutrophil	oxidative	burst	reactions.	Mutations	in	NCF2	can	lead	to	chronic	granulomatous	
disease	which	 exhibits	 granulomatous	 inflammation,	 a	 pathognomonic	 pathological	 lesion	
with	 a	 predilection	 for	 the	 upper	 and	 lower	 respiratory	 tracts	 in	 patients	 with	 PR3-AAV.	
Furthermore,	 there	 were	 significant	 interactions	 between	 these	 SNPs	 (rs112635299	 and	
rs28929474)	and	the	promoters	of	several	candidate	target	genes,	some	of	which	are	involved	
in	 anti-bacterial	 (SERPINA5)	 and	 anti-inflammatory	 (SERPINA12)	 responses,	 altogether	






the	 whole	 blood	 (318)	 and	 total	 PR3	 plasma	 levels	 while	 the	 SERPINA1	 Z-allele	 causes	 a	
reduction	in	circulating	A1AT	levels.	These	risk	alleles	 lead	to	an	altered	availability	of	PR3	
autoantigen,	 together	 with	HLA	 associated	 genetic	 predisposition	 (e.g.	HLA-DPB1*04:01),	



















positive	and	15%	ANCA	negative	 individuals)	 and	healthy	 controls	 (n	=	41),	of	which	 they	
attributed	the	discrepancy	with	prior	studies	to	the	differences	in	methodology	including	the	
location	within	 the	nasal	 cavity	where	 the	 swabbing	was	performed.	 In	 contrast,	 a	 recent	
abstract	by	Kronbichler	et	al,	where	they	investigated	the	changes	of	the	nasal	microbiome	














IsdC	 and	 transmembrane	 complex	 IsdEF-FhuD)	 and	 metabolises	 (IsdD	 and	 IsdI)	 heme	
molecules	to	extract	the	 iron	atom.	 IsdB,	which	 is	an	extracellular	receptor,	 functions	as	a	
central	 component	 of	 removing	 heme	 from	 haemoglobin	 (403,	 404).	 It	 contains	 two	
structurally	conserved	NEAr-iron	Transporter	(NEAT)	domains,	NEAT1	(Hb	binding)	and	NEAT2	
(heme	binding),	that	function	synergistically	(405).	The	NEAT	domains	are	also	found	in	other	









Yeung	 and	 colleagues	 recently	 demonstrated	 that	 there	was	 a	 heavily	 biased	 use	 of	 two	
immunoglobulin	heavy	chain	germlines	generated	antibodies	that	neutralise	NEAT1	(IGHV4-
39)	 and	 NEAT2	 (IGHV1-69)	 domains	 respectively.	 Notably,	 they	 found	 that	 the	 antibody-
antigen	binding	mechanism	was	nearly	identical	despite	antibody	derivation	from	different	
donors.	Though	being	a	part	of	 the	adaptive	 immune	system,	 the	authors	postulated	that	
both	IGHV1-69	and	IGHV3-49	might	have	evolved	under	selection	pressure	to	encode	binding	
motifs	 that	 are	 capable	 of	 recognising	 and	 neutralising	 structurally	 conserved	 protein	
domains,	which	are	involved	in	iron	acquisition	across	different	pathogens.	More	importantly,	
the	authors	demonstrated	that	allelic	variation	at	position	50	 in	 IGHV1-69	 (G50R,	the	 lead	
		
	104	
SNP	 in	 chr14q32.33	 locus)	 completely	 abolished	 NEAT2	 binding	 presumably	 from	 steric	









influenza	 vaccination	 (413,	 414),	 which	 raises	 another	 possibility	 that	 influenza	 antigens	
might	serve	as	a	trigger	for	AAV	induction	in	genetically	predisposed	individuals.	Although	the	
roles	of	Ig	germ-line	polymorphisms	have	not	been	extensively	explored,	there	is	a	growing	





study	provides	conclusive	evidence	 that	PR3-AAV	 is	a	polygenic	disease.	A	majority	of	 the	
candidate	genes	identified	are	involved	in	the	immune	pathway,	offering	new	leads	into	the	
pathogenesis	of	PR3-AAV.	Our	study	also	presents	a	plausible	host	genetic	factor	(IGHV1-69;	













The	 epidemiological	 and	 clinical	 manifestations	 of	 AAV	 differ	 geographically.	 The	 overall	
annual	 incidence	 of	 AAV	 was	 similar	 between	 Japan	 and	 the	 UK	 (36).	 However,	 the	
predominant	subtype	observed	in	Japan	was	MPA,	accounting	for	83%	of	patients	and	more	
than	 80%	 were	MPO-ANCA	 positive.	 A	 similar	 pattern	 was	 observed	 in	 China	 (415,	 416)	
although	population-based	data	is	lacking.	Previous	GWAS	in	the	European	population	have	
only	 identified	 one	 genome-wide	 significant	 locus	 within	 the	 HLA	 region	 (HLA-DQ)	 to	 be	
associated	 with	 MPO-AAV	 (70,	 71)	 while	 genetic	 data	 from	 Asian	 countries	 are	 scarce,	
primarily	candidate	gene	analyses	and	most	genetic	variants	are	not	widely	confirmed	except	







































GWAS2	 was	 reduced	 from	 1.242	 to	 1.094	 after	 fitting	 20	 PCs	 as	 covariates	 in	 a	 linear	





























Association	 tests	 were	 performed	 on	 genotyped	 data	 and	 comparison	 between	 logistic	 regression	 with	 no	
covariates,	varying	numbers	of	principal	components	(PCs)	as	covariates	and	LMM	for	MPO-AAV	in	(A)	GWAS1	














































†OR	(95%	CI)	  yP	 †OR	(95%	CI)	 yP	 †OR	(95%	CI)	 ∆P	
‡rs2476601	 1p13.2	 114,377,568	 PTPN22	 A	 0.10	 1.52	(1.13-2.05)	 5.50	X	10-3	 1.52	(1.27-1.83)	 1.40	X	10-6	 1.49	(1.28-1.74)	 3.13	X	10-7	
‡rs6679677	 1p13.2	 114,303,808	 PTPN22	 A	 0.10	 1.50	(1.13-2.01)	 5.70	X	10-3	 1.52	(1.27-1.83)	 1.30	X	10-6	 1.48	(1.27-1.73)	 3.51	X	10-7	
rs115670873	 2p13.1	 74,171,061	 DGUOK,	TET3	 A	 0.93	 1.97	(1.05-3.68)	 3.50	x	10-2	 1.69	(1.38-2.08)	 8.50	x	10-7	 1.82	(1.46-2.27)	 7.60	x	10-8	
rs116522341	 6p21.32	 32,367,697	 BTNL2,	HLA-DQ	 G	 0.04	 4.80	(2.80-8.23)	 1.10	X	10-8	 5.11	(3.76-6.94)	 6.00	X	10-25	 4.80	(3.67-6.26)	 1.09	X	10-30	
rs79005509	 6q15	 90,850,730	 BACH2	 T	 0.02	 7.28	(3.21-16.52)	 2.00	X	10-6	 1.98	(1.33-2.95)	 8.90	X	10-4	 2.90	(2.00-4.20)	 1.90	X	10-8	
























by	 several	 functional	 studies	 as	 discussed	 in	 section	 1.4.2.	 It	 has	 been	 reported	 to	 be	
associated	with	a	wide	range	of	autoimmune	diseases	including	RA	(90,	417),	T1D	(91-93),	
thyroid	diseases	(95,	96),	Crohn’s	disease	(131),	alopecia	areata	(418),	vitiligo	(374)	and	SLE	
(129).	 Importantly,	 this	 variant	 showed	 the	 same	 direction	 of	 effect	 (i.e.	 same	 allele	
associated	with	higher	risk	of	MPO-AAV	and	other	autoimmune	diseases).	It	was	also	reported	
in	 the	VCRC	GWAS	 (71),	although	 the	p-value	 for	 the	MPO-AAV	subset	 fell	 just	below	the	
genome-wide	significance	threshold.	Furthermore,	the	PCHi-C	data	showed	 interactions	of	
this	SNP	with	multiple	gene	promoters	in	total	B	cell,	CD4	and	CD8	T	cells	(see	Table	4.4	and	


















HIPK1	 (homeodomain-interacting	 protein	 kinase-1)	 is	 one	 of	 the	 four	 highly	 related	
serine/threonine	 kinases	 identified	 as	 corepressors	 for	 several	 homeodomain-containing	
transcription	 factors	 and	 TNF-mediated	 cellular	 apoptosis	 (423).	 HIPK1	 is	 ubiquitously	
expressed	 and	 relatively	 abundant	 in	 the	 naïve	 B	 cells,	 CD8	 T	 cells,	 neutrophils	 and	





NRAS	 (also	 known	 as	 NRAS	 proto-oncogene,	 GTPase)	 encodes	 N-Ras	which	 is	 involved	 in	
regulating	 cell	 division.	 Mutations	 in	 NRAS	 causes	 autoimmune	 lymphoproliferative	
syndrome,	 which	 is	 characterised	 by	 an	 expansion	 of	 non-malignant	 lymphocytes	 due	 to	























































































independently	 been	 linked	 to	multiple	 inflammatory	 diseases	 including	 T1D	 (426),	 coeliac	
disease	(97),	Crohn’s	disease	(427),	vitiligo	(374),	SLE	(369)	and	MS	(428).	In	addition,	both	








BACH2	 is	 most	 abundantly	 expressed	 in	 the	 bone	marrow	 and	 immune	 system	with	 the	
highest	expression	found	in	germinal	centre	B	cells,	followed	by	naïve	B	cells,	CD4	T	cells,	class	
switched	memory	 B	 cells	 and	 CD8	 T	 cells	 (BLUEPRINT	 data	 release	 2016-08).	 It	 acts	 as	 a	
repressive	 transcription	 regulator,	 maintaining	 the	 balance	 of	 a	 network	 of	 all	 other	
transcription	factors	which	are	critical	for	B	and	T-cell	differentiation	and	maturation.	Its	role	
in	B-cell	development	has	been	studied	greatly	where	it	represses	the	expression	of	Blimp-1	
(a.k.a.	PR	domain	zinc	 finger	1)	 (432),	 to	decelerate	plasma	cell	differentiation	and	permit	
antibody	 class	 switch	 recombination	 (433-435).	 In	 T	 cells,	BACH2	 modulates	 networks	 of	
genes	that	control	T	cell	effector	lineages	(316),	balancing	differentiation	into	effector	cells	
and	development	of	FoxP3+	regulatory	T	cells	(Treg)	(436).	BACH2-/-	mice	exhibit	impaired	B-




















set	 are	 located	 in	 the	 region	 with	 evidence	 of	 chromatin	 signatures	 of	 active	 enhancers	
(enrichment	for	histone	H3K27ac,	Figure	4.4).	None	of	these	variants	has	been	reported	to	be	







(Figure	 4.5).	 The	 PCHi-C	 data	 showed	 evidence	 of	 interactions	 between	 these	 potential	
variants	with	promoters	of	several	candidate	genes	in	GM12878	cell	line.		
	
ANKRD11	 encodes	 a	 protein	 that	 contains	 multiple	 ankyrin	 domains,	 which	 allows	 its	
interaction	with	other	proteins	such	as	histone	deacetylases	(chromatin	modifying	enzymes)	
to	modulate	gene	expression.	For	example,	 it	has	been	shown	to	 inhibit	 ligand-dependent	
transactivation	 by	 recruiting	 histone	 deacetylases	 to	 p160	 coactivators/nuclear	 receptor	
complex	(438).	Its	critical	role	in	regulating	transcription	might	explain	the	high	number	of	










slowly	 progressive	weakness	 and	 spasticity	 in	 the	 lower	 limbs.	Notably,	 the	 risk	 allele	 for	
MPO-AAV	(rs2965955:C)	has	opposing	directions	of	effect	on	SPG7	expression	in	whole	blood	













Top	 to	 bottom	 panels:	 Genomic	 position	 (hg19),	 representative	 RefSeq	 genes,	 PCHi-C	 data	 (Mifsud	 et	 al	 –	












Following	 a	 meta-analysis	 of	 GWAS1	 and	 GWAS2,	 there	 were	 two	 peaks	 showing	 the	
strongest	 associations	 in	 the	 MHC	 region,	 spanning	 approximately	 300	 kb	 region	 and	


















I	 performed	 a	 stepwise	 conditional	 association	 analysis	 in	 this	 region	 to	 confirm	 the	
independent	signals	and	since	the	HLA	imputation	was	performed	on	the	GWAS2	dataset,	I	
focused	 on	 the	 same.	 The	 lead	 SNP	 for	 the	 weaker	 cluster	 in	 GWAS2	 MPO-AAV	 was	
rs9275318,	 which	 is	 in	 complete	 LD	 with	 rs9275319	 (r2	 =	 1.0).	 Upon	 conditioning	 on	




















































































OR	 P	 OR	 P	 OR	 p	 OR	 P	
HLA-DRB1*04:04	 4.79	 3.10	x	10-30	 -	 -	 4.00	 8.70	x	10-16	 3.99	 1.70	x	10-19	
HLA-DQB1*03:02	 2.14	 4.20	x	10-17	 1.26	 0.045	 -	 -	 1.74	 1.70	x	10-5	

















and	 PR3-AAV	 samples	 directly	 with	 one	 another	 independent	 of	 controls	 (“within-case”	






























interactions	 between	 this	 SNP	 with	 CTLA4,	 CD28	 and	 RNU6-474P	 (Figure	 4.8).	 Genetic	







Top	 to	 bottom	 panels:	 Genomic	 positions	 (hg19),	 representative	 RefSeq	 gene,	 PCHi-C	 data	 (Mifsud	 et	 al	 –	
GM12878	cell	line),	SNPs	association	with	AAV	where	the	filled	red	circle	indicates	the	lead	SNP	(rs1863800),	


























































3.03	x	10-2	 75.20	 17.00	 0.74	




























3.64	x	10-3	 3.99	 0.35	 62.40	




























8.55	x	10-23	 -	 -	 -	












2.44	x	10-73	 -	 -	 -	












1.52	x	10-3	 3.13	 40.30	 9.35	












3.10	x	10-2	 1.95	 7.40	 45.10	












5.91x	10-8	 4.77	 0.00	 65.10	




























1.04	x	10-7	 2.95	 83.50	 0.00	
















MPO-AAV	 is	 summarised	 in	Table	4.8.	 Three	of	 the	12	 loci	 associated	with	AAV	displayed	
strong	evidence	of	a	 shared	causal	variant	between	MPO-AAV	and	PR3-AAV	of	equivalent	
effect	size	in	the	same	direction	(CTLA4,	PTPN22,	DGUOK-TET3).	Although	rs1863800	(CTLA4)	





signals.	 Furthermore,	 in	 the	 within-case	 analysis,	 none	 of	 these	 SNPs	 achieved	 nominal	
significance,	supporting	that	the	signals	at	these	loci	are	not	subgroup	specific.	Notably,	the	





ANKRD11-SPG7)	 while	 six	 risk	 loci	 were	 PR3-AAV	 specific	 (HLA-DP,	 PRTN3,	 SERPINA1,	
BCL2L11-MIR4435-2HG,	EBF3-MGMT	and	IGHV1-69)	(Figure	4.10).	In	the	within-case	analysis,	




In	 summary,	 both	 colocalisation	 and	 within-case	 analysis	 provide	 robust	 evidence	 of	 a	
differential	genetic	basis	of	MPO-AAV	and	PR3-AAV	at	the	HLA	region	and	seven	non-HLA	loci	








Three	 risk	 loci	 are	 shared	 between	MPO-AAV	 and	 PR3-AAV	 and	 their	 associations	 with	 other	 autoimmune	
diseases	 in	genome-wide	association	studies	obtained	from	the	Phenoscanner	and	the	NHGRI-EBI	Catalog	of	

































PTPN22).	Apart	 from	SERPINA1,	 the	 strongest	effect	 size	was	observed	 in	 the	HLA	 region.		
Three	 independent	HLA	signals	were	confirmed	to	confer	 susceptibility	 for	PR3-AAV	while	
there	was	one	for	MPO-AAV.	Of	these	12	loci,	three	displayed	strong	evidence	for	a	shared	
causal	variant	between	MPO-AAV	and	PR3-AAV	(PTPN22,	DGUOK-TET3	and	CTLA4),	which	are	
also	 implicated	 in	 a	 wide	 range	 of	 autoimmune	 diseases.	 Three	 risk	 loci	 were	MPO-AAV	
specific	and	these	include	BTNL2-HLA-DQ,	BACH2	and	ANKRD11-SPG7	while	six	risk	loci	were	
PR3-AAV	 specific	 consisting	 of	 HLA-DP,	 BCL2L11-MIR4435-2HG,	 EBF3-MGMT,	 SERPINA1,	

















could	 be	 due	 to	 common	 HLA	 alleles,	 Li	 and	 colleagues	 previously	 estimated	 genetic	







associations	 and	 by	 far	 have	 the	 greatest	 genetic	 effect	 on	 the	 risk	 of	 developing	 AAV.	
Furthermore,	 in	 population-based	 studies,	 the	 estimate	 of	 genetic	 effect	 that	 is	 shared	






eQTL	data	support	 that	 the	 lead	variant	 (rs79005509:T),	which	 lies	 in	 the	distal	 regulatory	
region,	is	likely	to	regulate	the	expression	of	BACH2	through	an	interaction	with	its	promoter	
(321)	 in	CD4+	 and	CD8+	 T	 cells,	 potentially	 influencing	 the	binding	affinity	of	 transcription	
factors.	The	risks	allele	reduces	BACH2	mRNA	expression	(318)	and	might	consequently	lead	


















CTLA-4	 is	an	 important	negative	 regulator	of	T-cell	 activation	and	 it	 is	 implicated	 in	many	
organ-specific	autoimmune	diseases.	The	lead	variant	in	this	locus	is	a	known	eQTL	where	the	
risk	 allele	 (rs1863800:C)	 is	 associated	 with	 a	 lower	 expression	 of	 CTLA4	 but	 a	 higher	
expression	 of	 ICOS	 in	 the	 whole	 blood	 (318).	 ICOS	 (a.k.a	 CD278)	 is	 a	 CD28-superfamily	
costimulatory	 molecule	 that	 is	 expressed	 on	 T	 cells	 upon	 activation.	 In	 addition,	 other	
reported	autoimmunity-susceptibility	variants	 in	this	region	 including	rs231775,	rs3087234	
and	 rs231806,	which	 are	 in	 high	 LD	with	 the	 lead	 SNP,	 have	 been	demonstrated	 to	 have	
functional	 effects	 on	CTLA4	 transcription	 (in	 both	 CD4+	 T	 cells	 and	 CD8+	 T	 cells),	 splicing,	
production	 of	 the	 soluble	 form	 of	 CTLA-4	 and	 post-translational	modifications	 (448-451).	
Taken	all	together,	individuals	carrying	the	risk	alleles	might	have	a	lower	activation	threshold	
of	 T	 cells	 and	 thus	 contribute	 to	 T-cell	 activation	 and	 autoimmune	 disease	 susceptibility.	
There	 is	an	ongoing	clinical	 trial	 (ABROGATE,	ClinicalTrials.gov	 Identifier:	NCT02108860)	to	

















































as	 programmed	 cell	 death	 and	 is	 characterised	 by	 cell	 shrinkage,	 nuclear	 and	 chromatin	
condensation,	DNA	fragmentation,	membrane	blebbing,	phosphatidylserine	externalisation	
and	 formation	 of	membrane-bound	 apoptotic	 bodies.	 These	 apoptotic	 bodies	 are	 rapidly	
phagocytosed	 by	 either	 macrophages	 or	 adjacent	 epithelial	 cells	 to	 avoid	 inflammatory	
response.	In	vitro,	the	apoptotic	bodies	and	the	remaining	cell	fragments	ultimately	swell	and	















that	 ultimately	 influence	 the	 insertion	 of	 Bax	 and	 Bax-like	 proteins	 into	 the	 outer	
mitochondrial	membrane,	leading	to	cytochrome	C	release	and	activation	of	caspase9/Apaf-
1	 (apoptotic	protease	activating	factor	1)	apoptosome.	Bims	 is	 the	most	potent	 inducer	of	
apoptosis.	 The	 lifespans	of	myeloid	and	 lymphoid	 cells	 are	 substantially	 increased	 in	Bim-









gene	 in	a	poised	state	and	enabling	 rapid	control	of	apoptosis	 in	 response	 to	pro-survival	
cytokines	 (380).	MIR4435-2HG	 is	 highly	 conserved	 across	 species	 and	 is	 localised	 in	 the	



































CD16+	neutrophils	 55	 21	 1	
CD14+	monocytes	 40	 17	 0	
CD8+	T	cells	 56	 20	 1	
CD4+	T	cells	 22	 9	 1	






expression,	 a	 clone-based	 allele-specific	 expression	 assay	 was	 used	 to	 analyse	 BCL2L11	
transcription	 in	 neutrophils	 from	 eight	 heterozygous	 healthy	 individuals.	 This	 technique	
facilitated	 a	 direct	 comparison	 between	 the	 amount	 of	 BCL2L11	 pre-mRNA	 that	 was	
transcribed	 from	 each	 allele	 and	 ensured	 that	 the	 external	 factors	 affected	 both	 alleles	
equally.	 Under	 basal	 conditions	 (unstimulated,	 time	 0	 hr),	 we	 observed	 allele-specific	
































































same	 causal	 variant	 at	BCL2L11-MIR4435-2HG	 region,	 we	 then	 asked	whether	 eosinophil	
count	was	causally	related	to	PR3-AAV.	To	address	this	question,	we	performed	Two-sample	
Mendelian	Randomisation	 analysis	 using	 the	 summary	 statistics	 from	GWAS	of	 eosinophil	
counts	 (346),	 consisting	 of	 209	 conditionally	 independent	 genome-wide	 significant	 SNPs.	
After	excluding	the	HLA	region,	147	of	these	variants	were	available	in	the	PR3-AAV	dataset	
for	 MR	 using	 the	 IVW	 method.	 We	 found	 that	 a	 higher	 eosinophil	 count	 was	 strongly	
associated	with	an	increased	likelihood	of	developing	PR3-AAV	(causal	estimate	=	0.249,	p	=	













Method	 Causal	Estimate	 95%	CI	 P-value	
Simple	median	MR	 0.593	 0.318	–	0.868	 0.000***	
Weight	median	MR	 0.243	 -0.040	–	0.525	 0.092	
Penalised	weighted	median	MR	 0.245	 -0.038	–	0.528	 0.090	
IVW	MR	 0.249	 0.028	–	0.470	 0.028*	
Penalised	IVW	MR	 0.299	 0.111	–	0.486	 0.002**	
Robust	IVW	MR	 0.263	 0.061	–	0.465	 0.011*	
Penalised	robust	IVW	MR	 0.304	 0.117	–	0.491	 0.001***	
MR	Egger	estimate	 0.086	 -0.441	–	0.613	 0.750	
MR	Egger	intercept	 0.007	 -0.015	–	0.030	 0.504	
	





























influence	gene	expression	 in	eosinophils	 and	 consequently	alter	eosinophil	 count	 through	
prolongation	 of	 cell	 survival.	We	 recruited	 eight	 pairs	 of	 healthy	 individuals	 via	 the	NIHR	
BioResource	Centre	Cambridge,	who	were	homozygous	for	either	the	major	or	minor	allele	
at	 rs13405741,	 and	 were	 matched	 for	 age	 and	 gender.	 Eosinophils	 were	 isolated	 from	
polymorphonuclear	 cell-rich	 fraction	 of	 peripheral	 blood	 by	 negative	 immunomagnetic	
selection.	 Eosinophils	 represent	 a	minor	 population	 of	 leukocytes	 in	 the	 peripheral	 blood	
(typically	between	2-5%)	and	therefore	cell	yield	following	isolation	varied	among	samples.	
We	first	examined	the	expression	of	BCL2L11	and	MIR4435-2HG	to	determine	whether	these	




points	 (Figure	 5.4A).	We	 then	 investigated	how	differences	 in	MIR4435-2HG	 transcription	

















(A)	 Representative	 photomicrographs	 of	 eosinophils	 at	 time	 0	 hr	 (top)	 and	 24	 hr	 (bottom)	 after	 incubation	
without	serum	depicting	the	morphological	features	of	apoptosis	including	DNA	fragmentation,	cell	shrinkage,	






















diminishes	 during	 granulopoiesis,	 reaching	 an	 almost	 undetectable	 level	 in	 the	 circulating	
mature	neutrophils	(Figure	5.5A,	RNA-seq	data	obtained	from	BLUEPRINT	datasets).	This	gene	
has	 two	 transcripts	 –	 canonical	 isoform	 (PRTN3-201)	 and	alternative	 isoform	 (PRTN3-202)	
which	 initiates	 transcription	 at	 a	 different	 promoter	 located	 in	 the	 intron	 1.	 Alternative	
splicing	was	first	reported	by	Chow	et	al	in	1977	(456).	It	is	an	important	biological	process	
that	 contributes	 to	 the	 diversity	 of	 protein	 isoforms	 of	 subtle	 functional	 differences,	 yet	
























PRTN3	 (318).	 In	 terms	 of	 disease-relevant	 cell	 type,	 there	were	 two	 studies	 investigating	
whether	 these	 variants	 had	 an	 influence	 on	 PRTN3	 expression	 in	 neutrophils	 with	























left	 axis).	 Right:	 The	 stages	 of	 granulopoiesis	 from	myeloblast	 to	 the	mature	 circulating	 neutrophil.	 During	
neutrophil	maturation,	 granulocytic	 cells	 change	 shape,	 acquire	 primary	 and	 specific	 granules	 and	 undergo	
nuclear	condensation	(Images	were	obtained	from	https://imagebank.hematology.org/).	








TaqManâ	 SNP	 genotyping	 assay.	 Following	 QC	 of	 the	 CD16+	 neutrophil	 gene	 expression	
datasets,	the	number	of	patients	included	in	the	eQTL	analysis	is	summarised	in	Table	5.4.	To	
evaluate	for	allelic	effects	of	rs62312296:	C	>	T	on	PRTN3	expression,	I	first	performed	whole	
transcript	 analysis	 and	 showed	 that	 in	 the	 CKD	 cohort,	 PRTN3	 transcript	 levels	 were	
significantly	higher	in	minor	(T)	allele	homozygotes	(risk	allele	for	PR3-AAV)	than	in	patients	
with	CC	or	CT	genotypes,	with	evidence	of	allelic	transcripts	dosage	effect	(ANOVA,	p	<	0.001;	







microarray	–	 two	probes	 for	exons	1	and	5	 respectively	and	one	probe	 for	 the	 remaining	
exons.	 I	detected	 significantly	higher	expressions	of	exons	3	 (ANOVA,	p	=	0.0362;	 test	 for	
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(A)	 qPCR	 using	 the	 TaqMan	 genotyping	 assays	 with	 probes	 targeting	 different	 exons	 showing	 differential	
expression	 of	PRTN3-201	 by	 genotype	 at	 rs62132296	 (left:	 test	 for	 linear	 trend,	 p	 =	 0.0005)	 and	 combined	
expression	of	PRTN3-201	and	PRTN3-202	(right:	test	for	linear	trend,	p	<	0.0001).	
(B)	 PRTN3	 expression	 quantification	 at	 gene	 level	 using	 the	 RNA-seq	 data	 of	 CD16+	 neutrophils	 showing	
comparable	 findings	 as	 microarray	 and	 qPCR	 analyses	 where	 higher	 expression	 of	 PRTN3	 was	 observed	 in	
patients	bearing	homozygous	risk	genotype	at	rs62132296	(test	for	linear	trend,	p	=	0.0249).		







Understanding	 the	 fundamental	 mechanisms	 of	 how	 genetic	 variants	 might	 exert	 their	
pathogenic	 effects	 is	 essential	 for	 the	 development	 of	 novel	 diagnostic	 and	 treatment	
avenues.	 Translating	 GWAS	 results	 into	 biologically	 relevant	 effects	 remains	 a	 major	
challenge,	although	 these	barriers	have	been	gradually	overcome	with	 recent	advances	 in	
technology,	statistical	and	bioinformatics	approaches,	along	with	publicly	available	genomic	







is	 associated	 with	 a	 higher	 expression	 of	MIR4435-2HG	 in	 eosinophils,	 which	 results	 in	
downregulation	of	BCL2L11	transcription	and	eventually,	reduced	apoptosis.	Prolongation	of	
cell	survival	leads	to	a	higher	eosinophil	count	which	underpins	the	pathogenesis	of	PR3-AAV.	
Although	we	 did	 not	 detect	 any	 differences	 in	BCL2L11	 mRNA	 levels	 by	 genotype	 in	 our	
experiments,	it	does	not	exclude	a	possible	role	of	BCL2L11	for	this	biological	process	as	the	



















patients	 (468).	 Schnabel	 et	 al	 found	 higher	 eosinophil	 cationic	 protein	 levels	 in	 the	
bronchoalveolar	lavage	fluid	from	GPA	patients	but	below	the	detection	limit	in	patients	with	
sarcoidosis,	which	 is	 a	 granulomatous	 disease	without	 vasculitis	 involvement	 and	 healthy	
controls,	 suggestive	 of	 eosinophil	 activation	 and	 degranulation	 (469).	 Nonetheless,	 it	 is	
difficult	to	ascertain	the	precise	role	of	eosinophils	in	disease	pathogenesis	as	these	studies	
are	predominantly	based	on	case	reports.	With	the	application	of	MR	methodology,	our	study	




granules	 for	 red	 dye	 eosin	 (470)	 and	more	 than	 90%	of	 eosinophils	 reside	 in	 the	 tissues,	
particularly	bone	marrow,	gastrointestinal	 tract,	 thymus	and	the	endometrial	 lining	of	 the	
uterus	(471).	Eosinophil	differentiation	and	expansion	occur	in	the	bone	marrow	under	the	
influence	 of	 a	 number	 of	 transcription	 factors	 (GATA-binding	 factor	 1,	 PU.1	 and	 CCAAT-
enhancer-binding	 proteins)	 and	 several	 cytokines	 (IL-3,	 IL-5	 and	 GM-CSF)	 (459).	 The	




defence	 against	 helminths	 and	 allergic	 inflammation	 such	 as	 asthma,	 Lee	 and	 colleagues	
recently	hypothesised	that	resident	tissue	eosinophils	might	be	essential	for	local	immunity,	
remodelling	and	 repair	 in	both	health	and	disease	 (471),	as	accumulating	data	 supporting	
their	 immunomodulatory	 abilities	 through	 expression	 of	 cytokines	 and	 growth	 factors	





been	 observed	 in	 eosinophil-deficient	mice	 both	 at	 steady	 state	 and	 after	 immunisation,	
which	improved	momentarily	following	eosinophil	reconstitution	(473).	
	




investigated	 the	 functional	and	activation	 status	of	eosinophils	 in	a	 cohort	of	120	healthy	
controls	 and	 98	 GPA/MPA	 patients,	 of	 whom	 88%	 were	 on	 active	 treatment	 with	
immunosuppression	and	78%	in	disease	remission.	The	authors	reported	a	lower	percentage	
of	eosinophils	in	the	peripheral	blood	of	AAV	patients	with	altered	expression	of	cell	surface	




in	 tissues	 and	 contribute	 to	 inflammation	 (474).	 However,	 one	 must	 be	 cautious	 in	
interpreting	 the	 results	 as	 they	 could	 potentially	 be	 confounded	 by	 immunosuppressive	
treatment	particularly	glucocorticoids,	which	are	known	to	 induce	eosinophil	apoptosis	by	
inhibiting	survival	prolonging	signals	and	influence	the	levels	of	NADPH	oxidase	subunits	and	















we	 were	 conducting	 experiments	 to	 assess	 whether	 the	 identified	 variant	 exerted	 its	





by	 genotype	 at	 rs62132296	 in	 neutrophils.	 These	 data	 agree	with	 the	 proteomic	 analysis	
where	higher	plasma	levels	of	PR3	were	observed	in	individuals	carrying	the	risk	alleles	(319).	
Although	we	detected	 the	expression	of	 the	alternative	 transcript	 (PRTN3-202)	 in	PMN	of	
healthy	 controls	 and	 AAV	 patients,	 we	 were	 not	 able	 to	 determine	 differential	 isoform	











prolonging	 eosinophil	 survival.	 The	 current	 paradigm	 of	 the	 pathogenesis	 of	 AAV	 focuses	
primarily	on	neutrophils,	monocytes	and	lymphocyte-dependent	mechanisms.	This	study	is	
an	 important	 step	 towards	 understanding	 the	 role	 of	 eosinophils	 in	 vasculitis	 other	 than	






AAV	 is	 a	 rare	 autoimmune	 disorder	 that	 is	 associated	 with	 substantial	 morbidity	 and	
mortality.	The	aim	of	this	study	was	to	unravel	the	genetic	basis	of	PR3-AAV	and	MPO-AAV	
independently	in	order	to	improve	our	understanding	about	the	pathogenesis	of	disease	and	





PR3-AAV,	 including	 HLA-DPB1*04:01-HLA-DQB1*06:02-HLA-DRB1*15:01,	 HLA-DPB1*04:02	
and	HLA-DPA1*01:03-HLA-DPB1*02:01,	which	were	distinct	from	MPO-AAV,	conferred	by	an	
extended	 haplotype	 encoding	 HLA-DRB1*04:04-HLA-DQA1*03:01-HLA-DQB1*03:02.	 Using	
Bayesian	methods	to	define	credible	sets	from	the	GWAS	results,	together	with	integration	
of	 multi-sourced	 genomic	 datasets	 consisting	 of	 functional	 annotation,	 gene	 expression,	
methylation	 and	 PCHi-C	 data,	 we	 were	 able	 to	 identify	 candidate	 genes	 that	 provide	
potentially	important	biological	insights	into	disease	pathogenesis.	
	
Further	 analyses	 based	 on	 genotyped	 common	 variants	 suggested	 a	 significant	 positive	
genetic	correlation	between	PR3-AAV	and	MPO-AAV,	comparable	to	that	observed	between	
UC	and	Crohn’s	disease,	supporting	that	both	conditions	share	a	strong	genetic	architecture.	
The	 three	 risk	 loci	 that	are	common	to	both	PR3-AAV	and	MPO-AAV	 (PTPN22,	CTLA4	 and	
DGUOK-TET3)	also	share	commonalities	with	a	range	of	other	autoimmune	diseases	and	have	













eosinophilia	 nor	 extravascular	 eosinophilia	 are	 universal	 clinical	 features	 of	 PR3-AAV.	We	
confirmed	a	causal	association	between	higher	eosinophil	numbers	and	increased	risk	of	PR3-
AAV	 but	 not	 MPO-AAV,	 using	 two-sample	 MR	 and	 publicly	 available	 GWAS	 summary	
statistics.	This	effect	could	partly	be	modulated	by	MIR4435-2HG	 through	prolongation	of	
eosinophil	survival.	Very	little	is	known	about	the	role	of	eosinophils	in	the	pathogenesis	of	
PR3-AAV.	This	 is	an	area	worthy	of	 further	 research	efforts	with	potential	 for	becoming	a	
target	for	new	therapeutics.	
	















the	 LMM	 model	 for	 genetic	 association	 testing,	 which	 has	 been	 shown	 to	 be	 better	 in	














are	 common	 to	 both.	 Secondly,	 the	 overall	 eosinophil	 yield	 was	 low	 during	 in	 vitro	
experiments	despite	the	use	of	the	immunomagnetic	purification	procedure,	which	is	a	highly	
reproducible	method	for	 isolating	eosinophils.	Therefore,	 I	did	not	have	adequate	cells	for	
time-course	 experiments	 to	 investigate	 time-dependent	 transcriptional	 responses	 under	
different	 conditions.	 As	 eosinophils	 represent	 only	 a	minority	 of	 the	 circulating	 leukocyte	
population,	 this	problem	could	be	addressed	by	 sampling	a	 larger	volume	of	whole	blood	
from	healthy	volunteers.	Thirdly,	we	did	not	detect	differential	PRTN3	 isoform	expression	
using	RNA-Seq	due	to	low	read	counts	despite	acquiring	approximately	30	million	reads	per	










research	 generating	 multi-omics	 datasets	 have	 driven	 the	 evolution	 of	 bioinformatics,	
bridging	 the	 gap	 between	 genetic	 association	 and	 biological	 function	 and	 eventually,	









unlikely	 that	we	will	 reach	a	 sufficiently	 large	power,	 contrary	 to	other	 common	complex	
diseases	such	as	hypertension	and	type	2	diabetes,	to	allow	low-frequency	and	rare	variants	
to	be	dissected	to	a	far	greater	extent.	An	alternative	approach	is	to	perform	whole	genome	
sequencing	 in	densely	affected	 families,	which	will	 enable	 identification	of	additional	 rare	






GWAS	 in	 different	 ethnic	 groups	 will	 provide	 valuable	 information	 including	 identifying	
genetic	determinants	that	are	shared	between	racial	groups	or	specific	to	a	subpopulation	




(cFDR))	 could	 be	 employed	 to	 address	 the	 question	 of	 genetic	 overlap	 as	 this	 statistical	








validation	 and	 exploratory	 experiments	 in	 primary	 cells	 or	 animal	 models	 to	 reveal	 the	
underlying	 biological	 basis	 of	 a	 GWAS	 signal.	 This	 can	 be	 facilitated	 by	 cutting-edge	
experimental	 techniques	 such	 as	 massively	 parallel	 reporter	 assays	 (MPRA)	 and	 various	
genome-editing	tools.	
	

































attributed	 to	 the	 SNP	 itself,	 rather	 the	 sequence	 containing	 the	 SNP	 allele.	 Furthermore,	
CRISPR-Cas9	technology	has	been	adapted	to	study	transcriptional	regulation	where	the	Cas9	
protein	is	altered	to	be	catalytically	dead	but	still	forming	a	protein	RNA-DNA	complex	with	
specifically	 engineered	 guide	 RNAs	 and	 an	 additional	 transcriptional	 activator	 (CRISPR	







Our	 data	 support	 a	 causal	 role	 of	 eosinophil	 count	 in	 the	 development	 of	 PR3-AAV.	
Eosinophils	 have	 long	 been	 perceived	 as	 non-specific	 destructive	 and	 cytotoxic	 cells	with	




to	 polarise	 T-cell	 function	 (through	 expression	 of	 Th1/2	 cytokines),	 to	modulate	 humoral	






markers	 on	 individual	 cells,	 allowing	 interrogation	 of	 cellular	 phenotype,	 function	 and	










with	 dysregulation	 of	 MIR4435-2HG	 which	 led	 to	 prolongation	 of	 eosinophil	 survival.	
Although	no	difference	in	BCL2L11	expression	between	groups	was	present,	our	results	have	
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